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ABSTRACT
The Effects of Polymorphisms of Viral Protein R of HIV-1 on the Induction of Apoptosis in
Primary Cells and the Characterization of Twelve Novel
Bacillus anthracis Bacteriophage
Jacob D. Fairholm
Department of Microbiology and Molecular Biology, BYU
Master of Science
Viral protein r (Vpr) of Human immunodeficiency virus type 1 (HIV-1) plays an
important role in the ability of the virus to infect cells and cause disease. Two polymorphisms to
Vpr have been shown to result in differences in disease progression in infected individuals.
R36W tends to result in rapid disease progression while R77Q results in long-term nonprogression. In order to better understand how these polymorphisms result in these different
disease phenotypes, our lab has recently shown that in cell culture, the R36W polymorphism
results in increased viral replication and greater induction of cell death. On the other hand,
infection with R77Q results in increased G2 cell cycle arrest and increased induction of
apoptosis. In this thesis, we have attempted to study how these two polymorphisms affect the
ability of HIV-1 to cause cell death in primary CD4+ cells. We show that infection by a Vpr
knockout virus results in increased apoptosis while infection with R77Q and R36W result in
decreased apoptosis. Additionally, R77Q infection results in increased p24 production. Further,
we attempted create a Rag2-/- γc-/- humanized mouse model in order to better study roles of these
polymorphisms in vivo.
An additional goal of this thesis was to characterize twelve novel Bacillus anthracis
bacteriophage. B. anthracis is gram positive, anaerobic, rod best known for being the causative
agent of anthrax. Bacteriophage, viruses that infect bacteria, have been used to identify bacterial
contamination and to treat infection. Herein, we report the isolation, sequencing, and
characterization of twelve novel phages that infect B. anthracis. The genomes were annotated
using DNA Master and BLASTp. Hypothetical proteins were analyzed with Phyre2 to predict
possible functions based on protein structure, revealing over 100 new predicted functions.
Dotplot generation showed that these phages group into four distinct clusters. By running the
major portal protein of one representative of each cluster through BLASTp, we have identified
the closest relatives to our novel phages and placed them into their respective genera and groups.

Keywords: HIV-1, Vpr, AIDS, Rag2-/- γc-/- humanized mice, apoptosis, primary CD4+ cells
Bacillus anthracis, bacteriophage
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CHAPTER I: INTRODUCTION TO HIV-1 AND BACTERIOPHAGE
Introduction
A Brief History of Virology
The study of viruses has its origins in the study of bacteria. In 1884, Robert Koch and
Friedrich Loeffler presented four postulates aimed at helping microbiologists identify the cause
of disease (1). Using these postulates, 19th century bacteriologists quickly identified the
etiological agents of anthrax, cholera, and typhoid fever. Koch’s postulates also inspired a
German agricultural chemist named Adolph Mayer to begin seeking to identify the etiological
agent of tobacco mosaic disease (2). In 1886, Mayer found that inoculating healthy plants with
the juice created by crushing up diseased plants was enough to cause the inoculated plant to
become sick. When examining this juice under a microscope, however, he failed to identify any
bacteria that could serve as the cause of the disease. Thus, Mayer concluded that the etiological
agent could not be cultured nor seen.
Investigations into the cause of tobacco mosaic disease would eventually lead to the first
identification of a virus and the birth of the field of virology. In 1892, Russian scientist Dmitri
Ivanovski found that tobacco mosaic disease was still transmittable even when the plant juice
was passed through a Chamberland filter (3). As these filters had pores small enough to block the
passage of bacteria, Ivanovski concluded that the agent wasn’t a bacterium but perhaps a
bacterial toxin. The final answer to the cause of tobacco mosaic disease came by way of Dutch
microbiologist Martinus Beijerinck in 1898. Once again repeating the experiments of Mayer and
Ivanovski, Beijerinck concluded that the sap was infectious even after being passed through
several Chamberland filters (4). However, Beijerinck took his experiments one step further.
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After inoculating the top layer of a thick slab of agar with infectious plant sap and allowing it to
incubate for several days, Beijerinck took the lower layer of agar and used it to inoculate healthy
plants. When these plants also became sick, Beijerinck concluded that the causative agent was
not like any known bacterium, but rather was contagium vivum fluidum, or infectious living
fluid, as it was able to flow through the agar to the lower layer. He called this living fluid a virus
after the Latin word meaning poison or toxin. Beijerinck continued to hypothesize that this virus
required the infection of living cells in order to survive and replicate (5). Thus, the tobacco
mosaic virus was identified.
Viral discovery continued at a rapid pace during the early twentieth century. Working
concurrently but independently of Beijerinck, Loeffler and Paul Frosch identified the cause of
foot and mouth disease to be a filterable virus, thus identifying the first virus that infects animals
(6). In 1902, yellow fever virus became the first human virus to be discovered following a
commission led by Walter Reed to eradicate the disease from Cuba (7). Thirteen years later, the
first bacterial virus was described in the work of Frederick Twort (5). Twort noticed that some
colonies of the micrococci he was growing appeared different in color and seemed to be filled
with cell debris without any living cells. When he inoculated healthy colonies with this debris,
they too became discolored and died. In 1915 Twort cautiously described this effect as being
caused by a bacterial virus. This conclusion was supported by the independent studies of
Canadian microbiologist Felix d’Herelle who discovered clear spots within his bacterial cultures.
After further investigation, d’Herelle found that these cleared plaques were related to the number
of viruses in the sample, as increasing dilutions resulted in fewer plaques. In his 1917 paper,
d’Herelle named these bacterial viruses bacteriophage, meaning devourer of bacteria in Greek.
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Thus, in a few short years many viruses infecting everything from plants and animals to humans
and bacteria were discovered, giving rise to the field of virology.
Although the field of virology was rapidly growing in the first half of the twentieth
century, there was still debate as to what actually constituted a virus. In 1927, Thomas Milton
Rivers published a review known as Filterable Viruses in which he attempted to define the term
virus and summarize everything currently known about these new biological agents (8). He
began his review by first attempting to unify the naming system of etiological agents that could
pass through filters. Up until that point, these agents were described as “invisible microbes”,
“filterable viruses”, “microplasms”, and many more. Recognizing that terminology was
important in creating a unified field of study, Rivers proposed a single term for all these agents,
filterable viruses. He continued to describe what is known about filterable viruses. Rivers
characterized filterable viruses as different from bacteria in that they can pass through
Chamberland filters, infection establishes lasting immunity, requiring living cells to survive, and
displaying no measurable respiration. Although many of Rivers’ observations continue to define
viruses today, he was quick to state that as the field of virology advances, many of the so-called
filterable viruses on his list would turn out to be some other kind of contagion. The 1930’s and
40’s were an important time in the history of virology as many studies aimed at identifying the
structure of viruses, using TMV and phages as models, revealed that viruses were composed of
nucleic acids and proteins (2, 6, 9). Finally, in 1957 French microbiologist Andre Lwoff
provided a clear and concise definition of a virus that continues to guide virology today (10, 11).
That definition described viruses as infectious, potentially parasitic, entities which possessed
only one type of nucleic acid, used that nucleic acid to replicate, were unable to undergo binary
fission, and did not have any metabolic properties (12). In 1966 the International Committee on
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Nomenclature of Viruses, now known as the International Committee on Taxonomy of Viruses,
was established to be the final say on what constituted a virus and how each newly discovered
virus should be classified (13).
HIV Life-Cycle
In 1981, an outbreak of rare cancers and opportunistic infections lead to the first
diagnosis of acquired immunodeficiency syndrome (AIDS) (14). Two years later, the etiological
agent was identified as a virus (15). Human immunodeficiency virus type 1 (HIV-1) is a member
of the Lentivirus genus of the Retroviridae family. Like other retroviruses, the genome of HIV-1
is composed of two copies of single stranded RNA that get reversed transcribed into DNA upon
infection (16).
HIV-1 is able to infect several cell types involved in the immune system by the binding
of viral protein gp120 to CD4 expressed on the cell surface. These target cells include CD4+ T
cells, monocytes/macrophages, and dendritic cells (17). Entry into the cell is facilitated by the
binding of one of many different co-receptors, the most prominent of which being CCR5 and
CXCR4, which also determine the virus’s tropism (18). Usage of CCR5 (R5 tropism) is
characteristic of early infection whereas usage of CXCR4 (X4 tropism) is characteristic of latestage infection and the transition towards AIDS. The binding of gp120 to both CD4 and a coreceptor results in a conformational change in viral protein gp41, allowing it to insert itself into
the host cell membrane. Another conformational change in gp41 brings the viral membrane in
contact with the cell membrane, allowing for the fusion of the two membranes and the entry of
the virus into the cell (19). Once inside the cell, the capsid containing the viral genome makes its
way to the nucleus. During this time, reverse transcriptase begins the process of reverse
transcribing the single stranded RNA genome into double stranded DNA. Recent evidence
4

indicates that while reverse transcription begins in the cytoplasm, it is completed within the
nucleus, where the capsid finally completely uncoats (20, 21). Upon entry into the nucleus, viral
DNA is then integrated into the host genome with the help of the viral enzyme integrase.
Integration can occur essentially anywhere in the host genome, but seems to favor those sites
where transcription is active (22). Proviral DNA is maintained by the host and propagated
through DNA replication and cell division, allowing for the establishment of latency (22).
Proviral transcription occurs using host transcription factors associated with immune
activation such as NF-κB (23). The resulting viral RNA transcript has four fates, it can 1) be
maintained at full length and be used as genomic RNA, 2) be maintained at full length and be
used as the mRNA for the Gag and Gag/Pro/Pol polyproteins, 3) be partially spliced to produce
the mRNA for the Vif, Vpr, and Env proteins, or 4) be completely spliced to produce the mRNA
for the Tat, Rev, and Nef proteins (24). The completely spliced mRNAs predominate during
early transcription while full length transcripts predominate after several hours of transcription
(25). Cellular and viral proteases then cleave the resulting polyproteins. Tat then returns to the
nucleus and acts as a trans-activator, promoting increased proviral transcription, while Rev helps
to transport both unspliced and partially spliced viral RNAs out of the nucleus (23, 26). Thus,
both Tat and Rev are vital for the effective transcription and translation of viral RNAs. Viral
protein Gag then drives virion assembly including the incorporation of two copies of genomic
RNA. The immature virion then exits the cell through budding, allowing it to obtain a lipid
envelope (27). Final maturation occurs after budding as viral protease continues to cleave
polyproteins and the subsequent proteins assemble to form an infectious, fully mature virion. The
virus is then ready to infect a new cell and start the whole process over again.
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Each stage in this viral life cycle can be targeted by anti-viral drugs in an effort to treat
and control infection. Entry into the cell can be blocked by several different drugs which work
by a variety of different mechanisms. Enfuvirtide is an FDA approved drug that blocks the fusion
of viral and cellular membranes by binding to gp41 and preventing the conformational change
necessary for fusion (28). Other entry inhibitors work by blocking the virus’ ability to bind to
CCR5, such as maraviroc, or CD4, such as the newly approved fostemsavir (29, 30). Once the
virus has entered the cell, reverse transcription can be inhibited by either nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) or non-nucleoside reverse transcriptase inhibitors
(NNRTIs). NRTIs, such as zidovudine, function by mimicking natural nucleotides but lack a 3’
OH group onto which a new nucleotide can be added. Thus, when an NRTI is incorporated into
the growing nucleotide chain, polymerization is terminated. (31). On the other hand, NNRTIs,
such as efavirenz, bind to and inhibit the activity of reverse transcriptase without being
incorporated into the growing nucleotide chain (32). Integration of viral DNA into the host
genome can be blocked by integration inhibitors such as raltegravir (33). Finally, because HIV-1
polyproteins must be

inhibitors, such as
nelfinavir, are an
effective way to limit
this late step in the
HIV life cycle (34).
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Figure 1.1: Timeline of HIV-1 Infection. HIV-1 infection typically consists of three
timepoints, acute infection, latency, and AIDS. CD4+ T cell levels are represented
in blue. Viral load (HIV RNA copies/ml) is represented in red. Exact timeframe
varies.
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Because HIV is prone to mutations, drug resistance often arises during treatment. Thus, effective
treatment uses a cocktail of drugs from different classes, known as highly active anti-retroviral
therapy (HAART) (35). HAART has greatly improved the life expectancy of patients infected
with HIV and lifetime adherence to HAART can allow patients to live a relatively normal life
(36, 37).
HIV-1 infection can be divided into three main time points (Fig. 1.1). The first stage of
infection is characterized by high viral load but also high immune activation resulting in general
flu-like symptoms. The middle stage is characterized by low but chronic viral load as latency is
established. AIDS is the final stage where there is a spike in viral load and a sudden drop in
CD4+ T cell levels (18, 38). Clinically, AIDS is defined as a drop in CD4+ T cell levels below
200 cells per microliter of blood (39). As CD4+ T cells are critical for the proper functioning of
the immune system, their infection and destruction by HIV-1 results in the many
immunodeficiencies characterized by AIDS.
Role of Vpr
This work will focus on one protein of interest in the HIV-1 proteome known as viral
protein R (Vpr). Vpr is a small, 96 amino acid long, accessory protein that is highly conserved
across the lentiviruses, suggesting that it plays an important role in the viral life cycle and
pathogenesis (40). HIV-1 expresses Vpr in three different conformations throughout infection:
cell-associated,
virionassociated, and
free or secreted
Vpr (41).

vpr
LTR

gag

nef

vpu
env

vif
pol

LTR

tat
rev

Figure 1.2: Map of the HIV-1 Genome. Long terminal repeats (LTR) are indicated in
orange. Major structural and replication genes gag, pol, and env are indicated in green.
Regulatory genes tat and rev are indicated in yellow. Accessory genes vif, vpr, vpu, and
nef are represented in blue.
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Virion-associated Vpr is able to begin functioning as soon as infection is established despite the
late expression of the vpr gene and its cytopathic effects are seen even in the instance of nonproductive infection (42) (Fig. 1.2).
Vpr is involved in a number of important viral functions across the life cycle of HIV-1.
During or after reverse transcription, Vpr helps facilitate the transport of the pre-integration
complex (composed of cDNA, integrase, and a number of other host and viral factors) into the
nucleus. This step is critical for HIV-1 to be able integrate its genome into the host genome (43).
Another important role of Vpr is the induction of G2 cell cycle arrest, thought to be important for
viral gene expression (42). Virion production is driven by LTR-induced gene expression which is
most active during the G2 phase (44, 45). Also linked to this ability to induce G2 arrest is the
ability of Vpr to induce apoptosis (46). Finally, Vpr plays a role in immune avoidance by
interacting with NF-κB and inhibiting the production of many antiviral cytokines (47). Although
considered an accessory protein, these many functions of Vpr greatly enhance the virulence of
the virus. While the expression of Vpr is not required for the productive infection of T cells, it is
required for the infection of macrophages (48). As macrophages are nondividing cells, Vpr’s role
in assisting the transport of the pre-integration complex into the nucleus is necessary for the viral
genome to reach the host genome (49). Additionally, Vpr was found to downregulate the activity
of macrophage mannose receptor which typically targets and prevents proper expression of the
viral Env protein (50). Thus, by blocking this action, Vpr allows for full expression of Env and
the assembly of infectious virions.
Mechanisms by Which Vpr Induces G2 Arrest and Apoptosis
The ability of Vpr to induce apoptosis is still a greatly debated topic. Many studies have
attempted to answer the question and have arrived at opposing conclusions. Vpr itself does not
8

have any enzymatic activity, thus all of its functions are due to its ability to bind to and modify
the activity of cellular proteins and enzymes (51). The induction of apoptosis is at least in part
linked to the ability to induce G2 cell cycle arrest, as arrest is often a precursor to apoptosis (52).
Thus, many studies that attempt to determine the mechanism by which Vpr induces apoptosis do
so by first looking for mechanisms of G2 arrest. There seems to be five main methods by which
Vpr induces G2 arrest and apoptosis in target cells: 1) modifying the activity of the
DDB1/Cul4A ubiquitin ligase complex, 2) inhibiting the activation of the B1/p34Cdc2 cyclin
complex, 3) modifying transcription by interaction with transcription factors, 4) induction of the
DNA damage response by ATR, and 5) inducing mitochondrial membrane permeability by
binding to both ANT and VDAC (Fig. 1.3) (51-54). These methods are not mutually exclusive
and may work together or independently to induce these effects.
Research into how Vpr induces G2 arrest and apoptosis has highlighted an interesting
interaction between Vpr and a protein known as DCAF1. This interaction was first identified by
a coprecipitation assay and was quickly identified as important for the function of Vpr (55, 56).
First termed Vpr-interacting protein (RIP), then Vpr-binding protein (VprBP), the original
cellular function of DCAF1 was unknown until it was found to bind to the damaged DNA
binding protein 1 (DDB1) (57). DDB1 acts as an adapter molecule for the Cullin4A E3 ubiquitin
ligase complex (58). Vpr binds to DCAF1 which subsequently binds to DDB1 which binds to
Cul4A and modifies the function of the complex by recruiting substrates to be ubiquitinated and
later degraded by proteosomes. At least 38 cellular proteins are targeted for proteasomal
degradation by Vpr via the DCAF1/DDB1/Cul4A complex, many of which play a role in the cell
cycle and detection of DNA damage (59). Among these targets are the uracil-DNA glycosylases
UNG2 and SMUG1, the DNA replication factor CDT1, the DNA repair endonuclease Mus81
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and the helicase-like transcription factor HLTF (51, 53, 54). The degradation of all these proteins
has been shown to induce G2 arrest followed by apoptosis.
Vpr can also cause cell cycle arrest by blocking the activation of the B1/p34Cdc2 cyclin
complex. In eukaryotes, the cell cycle is regulated by the interaction of cyclins with cyclindependent kinases (CDK). To progress from the G2 phase to the M phase, cyclin B1 must bind
to CDK p34Cdc2 and be activated by the phosphatase Cdc25C removing two phosphate groups
from p34Cdc2 (51, 53). If the phosphatase activity of Cdc25C is inhibited, the cell will not
progress to the M phase and will arrest in G2. Vpr is able to bind to Cdc25C and prevent its
phosphatase activity, leaving the B1/p34Cdc2 complex in its inactive state (44, 60). It has also
been shown that Vpr can bind to 14-3-3 proteins which bind to and inactivate Cdc25C (61).
Thus, Vpr can directly cause G2 arrest by preventing the proper activation of the B1/p34Cdc2
cyclin complex.
Transcriptional regulation by Vpr has also been shown as a mechanism for causing G2
arrest. Vpr is a known transactivator of the LTR, enhancing viral gene expression. This LTR
transactivation is enhanced during G2 arrest (52, 53). The LTR contains binding sites for two
cellular transcription factors, NF-κB and Sp1. The leucin zipper-like domain of Vpr binds to Sp1
allowing it to bind to the LTR and promote transcription (62). This interaction has also been
shown to affect transcription of other cellular factors, including those involved in the cell cycle
(63). Vpr can affect global transcription by binding to and causing a conformational change to
the basal transcription factor TFIIB (64, 65). Vpr binding to the DDB1/Cul4A complex has also
been shown to deplete expression of Tet2, resulting in an increase in IL-6 expression, further
enhancing virion production (66). Thus, Vpr’s effect on transcription is both DDB1/Cul4A
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dependent and independent. More research is needed to better understand how Vpr driven
transcriptional modification affects both G2 arrest and apoptosis.
The DNA damage response via ataxia telangiectasia and Rad3-related kinase (ATR) is a
common way that cells induce G2 arrest. Vpr has also been shown to provoke this pathway. Vpr
is able to bind directly to DNA and induce double-strand breaks (67). However, since Vpr does
not exhibit any endonuclease ability, the breaks caused by Vpr binding to DNA must be caused
by recruitment of a yet unknown protein. Vpr further activates the ATR pathway by blocking
double-strand break repair by both homologous recombination and nonhomologous end joining
(68). Additionally, Vpr can bind to the DNA repair enzyme SLX4, leading to premature
activation of the SLX4 complex and the degradation of Mus81 in a DDB1/Cul4A dependent
manner (69). Thus, Vpr can induce G2 arrest by activating the ATR DNA damage response
pathway in both a DDB1/Cul4 dependent and independent manner. Activation of the ATR
pathway leads to G2 arrest by inhibiting the function of Cdc25C, resulting in an inactive
B1/p34Cdc2 complex (70).
Independent of its ability to induce G2 arrest, Vpr is also able to directly induce
apoptosis. Vpr binds to adenine nucleotide translocator (ANT), a member of the permeability
transition pore complex (PTPC) (71). Additionally, Vpr can also bind another member of the
PTPC, the voltage dependent anion channel (VDAC) (72). The binding of Vpr to both ANT and
VDAC leads to the formation of channels in both the inner and outer mitochondrial membranes,
resulting in the release of cytochrome c (53). Cytochrome c release results in apoptosis through
the activation of caspase 9 and the subsequent activations of caspase 3 and 7 (73). Thus, there are
multiple complex ways by which Vpr can induce both G2 arrest and apoptosis. These
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mechanisms can work both dependently and independently and the inhibition of one does not
prevent the other.
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Figure 1.3: Mechanisms by Which Vpr Induces G2 Arrest and Apoptosis. There are 5 main ways by
which Vpr induces G2 arrest and apoptosis. 1) Binding to DCAF1 and modifying the activity of the
Cul4A ubiquitin ligase complex. 2) Activating the DNA damage response through ATR. 3) Blocking
the activation of the B1 cyclin complex by binding to Cdc25C. 4) Increasing mitochondrial membrane
permeability by binding to both ANT and VDAC. 5) Modifying the activity of transcription factors.
Black arrows represent dependent functions. Gray arrows represent functions that can be both
dependent and independent.
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R77Q and R36W Polymorphisms Affect Vpr Function and Pathogenesis
Interest in Vpr’s role in pathogenesis renewed when it was shown that different
polymorphisms result in differences in AIDS disease progression (Fig. 1.4). In 2003 Lum et. al.
sequenced the vpr gene isolated from HIV patients classified as either progressing or long-term
non-progressing (LTNP) based on their disease status. This sequencing revealed a change of the
arginine at amino acid 77 to a
glutamine (R77Q) in 80% of the
LTNP cohort compared to only
30% in the progressing cohort
(74). This association of R77Q
with LTNP was confirmed by an
additional study in 2006 (75).

Figure 1.4: Vpr Mutations Associated with Differences in Disease
Progression. In wild type Vpr, both the 36th and the 77th amino acid are
arginine. The arginine’s are substituted for tryptophane and glutamine
in R36W and R77Q respectively. The R36W mutation is associated
with rapid progression (RP) while the R77Q mutation is associated
with long-term non-progression (LNTP).

LTNP patients are able to
maintain their CD4+ T cell levels above the 200 cell/μL threshold for much longer than is typical
despite a lack of anti-retroviral treatments. Further interest into the effects of Vpr polymorphisms
on disease progression arose when a 2014 paper indicated that a change of the arginine at amino
acid 36 to a tryptophan (R36W) was associated with rapid disease progression (RP) (76). These
patients experienced a drop in their CD4+ T cell levels much more quickly than is typical of
HIV-1 infection. It is currently unclear how R77Q and R36W result in the observed differences
in disease progression.
Attempts to understand these differences have been hindered by differences in
experimental technique and infection models. Lum et. al. observed that infection with R77Q
resulted in a decrease in apoptosis induction (74). This was done using VSV-G pseudotyped
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virus infecting Jurkat T cells. However, an independent study using transfected T lymphocytes
expressing primary Vpr proteins indicated that expression of R77Q actually resulted in an
increase of apoptosis (77). These differences could be due to the way the Vpr protein was
delivered into the experimental system, either via pseudotyped infection or simply through
expression by transfection. The induction of G2 arrest seems to be an early indicator of apoptosis
as arrest tends to set off cell cycle checkpoints which lead to apoptosis (52). This has led to the
identification of cyclophilin A (CypA) as a potential binding partner of Vpr and a key in the
mechanism by which Vpr induces G2 arrest and apoptosis. Using Jurkat T cells that either could
or could not produce CypA and infecting them using fully functional HIVNL4-3, Zander et. al.
showed that CypA was critical for Vpr-induced cytopathic effects (78). On the other hand, Ardon
et. al. found that CypA was not required for Vpr-induced G2 arrest (79). This experiment was
also done using Jurkat T cells that were either CypAwt or CypA-/- infected with HIVNL4-3 with a
multiplicity of infection (MOI) of 0.5. Zander et. al. did not specify what MOI they used so it’s
possible that the difference in results seen
between these two studies was due to differences
in viral challenge and the amount of Vpr
Figure 1.5: Western Blot Confirming Vpr
Production. In order to ensure that our site-direct
mutagenesis still resulted in Vpr production, a
western blot was performed. GAPDH was used as
a loading control.

introduced to the system. Clearly, it is important
to have a unified experimental model in order to

elucidate the mechanisms by which Vpr induces its cytopathic effects.
R36W Results in Increased Viral Load While R77Q Results in Increased Apoptosis in Cell
Culture
Our lab recently undertook a study to investigate further the effects of the R36W and
R77Q Vpr polymorphisms in vitro. To improve upon the methods used in prior Vpr studies, our
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lab used whole, replication-competent HIVNL4-3 infecting the HUT78 cell line. The three aims of
the project included determining which polymorphism result in increased viral replication, which
result in increased cell cycle arrest, and which result in increased induction of apoptosis.
Understanding the results of each of these aims would shed greater light on why R36W and
R77Q result in their respective differences in observed phenotype.
Before the investigation could take place, the virus variants with the appropriate
polymorphisms had to be created. This was done via site-directed mutagenesis. The vpr gene was
cut out of the NL4-3 molecular clone, and cloned into the smaller pUC19 backbone, where the
site-directed mutagenesis took place. In addition to the R36W and R77Q strains, a vpr null strain
was created by replacing the start codon. Once the mutagenesis was complete, the respective vpr
genes were cloned back into the NL4-3 molecular clone. Virus stocks of each variant were then
created by transfection of HEK-293T cells and then titered using Ghost cells, which produce
green fluorescent protein when infected by HIV. Western blotting confirmed that the null
mutation blocked Vpr production while R36W and R77Q variants still produced detectable
levels of Vpr. Interestingly, the R77Q variant produced lower amounts of Vpr compared to WT
and R36W, the reason for which has yet to be determined (Fig. 1.5).
In order to determine how each
polymorphism affects the virus’s ability
to replicate, the team infected HUT78
cells and measured viral load via Q-RTPCR at days 3, 5, and 7 post infection
(Fig. 1.6). At day three, the only
significant difference was a 10-fold

Figure 1.6: Differences in Viral Load Measured by Q-RTPCR at 5 Days Post Infection. HUT78 cells were infected
with each viral variant and viral production was measure
via Q-RT-PCR. ** indicates a p-value ≤ 0.01.
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increase in viral load in R77Q compared to WT. However, at day 5, R36W showed a significant
increase in viral load compared to all the other strains. This difference stayed significant,
although to a lesser extent, at day 7. To confirm this result, the team stained the cells for p24, the
HIV capsid protein, and analyzed them by flow cytometry. This showed a significant increase in
p24 expression in the R36W infected population at all three time points compared to all other
viruses. Thus, it was determined that infection with an R36W harboring virus results in increased
viral replication.
Next, the investigators studied the ability to induce cell cycle arrest. At 7 days post
infection, the cells were stained with propidium iodide and examined via flow cytometry for
DNA content (Fig. 1.7). Cells arrested in the G2 phase will have twice as much DNA as cells in
the G1 phase while cells undergoing S phase will have an intermediate amount of DNA. Our
team found that infection with R77Q results in a statistically significant increase in cells arrested
in G2 phase when compared to all other infections. That said, all the infected samples had more
cells in G2 than the uninfected controls.

Figure 1.7: R77Q Results in Increased G2 Arrest. HUT78 cells were infected with each viral variant and
allowed to grow. At 7 days post infection, the cells were stained with propidium iodide to examine DNA content.
The blue peak represents cells in G1 phase, the yellow represents cells in S phase, and the green represents
cells in G2 phase.

Because G2 arrest is often associated with the induction of apoptosis, the ability of each
mutant to induce apoptosis was then examined. Again, at days 3, 5, and 7 post infection, cells
were stained with a fixable viability dye and annexin V to determine the percentage of cells that
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were either healthy (double negative), apoptotic (annexin V positive only), or dead/necrotic
(double positive). At all three time points, the samples infected by R77Q resulted in significantly
increased numbers of apoptotic cells (Fig. 1.8A). Interestingly, the R36W infected samples
showed increased numbers of dead but not apoptotic cells (Fig. 1.8B).
Through this study, our lab was able to determine that R36W results in increased viral
replication and increased cell death by necrosis. They also determined that R77Q results in
increase cell cycle arrest in the G2 phase and an increase in apoptosis. We believe that the
necrotic death induced by R36W results in an increase in inflammation, resulting in more
activated T cells being recruited to the site of infection. Thus, R36W viruses have more targets to
infect resulting in the RP phenotype.

A)

On the other hand, the apoptotic death
induced by R77Q does not result in
inflammation. Thus, R77Q spreads
slower resulting in the LTNP
B)

phenotype. However, these hypotheses
cannot be tested in cell culture alone.
Additionally, because HUT78’s are a
cancerous T cell line, their behavior

Figure 1.8: The Induction of Apoptosis and Cell Death by Vpr
Variants. HUT78 cells were infected with each viral variant. At
days 3, 5, and 7 post infection, a sample was taken and stained
for apoptosis and cell death using fixable viability dye and
Annexin V. A) R77Q results in an increase in the induction of
apoptosis. B) R36W results in an increased number of dead
cells in general. * indicates a p-value ≤ 0.05. ** indicates a pvalue ≤ 0.01

upon infection may differ from primary
cells. Thus, it is important to repeat
these studies in primary cells and in an
in vivo model.

Introduction to Bacillus anthracis and Bacillus Bacteriophages
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Bacillus anthracis has long been a favorite model among microbiologists. Even the
fathers of modern microbiology, Pasteur and Koch, used “the anthrax bacillus” in their studies.
B. anthracis is a gram-positive, non-motile, anaerobic, rod-shaped bacteria and is a member of
the Bacillus cereus group. This group includes seven closely related species including the
opportunistic human pathogen B. cereus and the insect pathogen B. thuringiensis (80). The main
distinguishing factor between B. anthracis and other members of the B. cereus group is the
presence of two virulence plasmids, pXO1 and pXO2, which code for anthrax toxin and a
capsule, respectively (81, 82). Like other members of the group, B. anthracis is capable of
forming spores that can survive long periods of time in soil (83). B. anthracis is best known for
being the etiological agent of anthrax. Due to its ability to form ultradurable spores that spread
easily, anthrax has been characterized as a Tier 1 select agent by the Centers for Disease Control
and Prevention. This means that it has high potential to be used as a biological weapon and is
thus subject to much oversight and control.
Bacteriophage research has continued at rapid pace since the work of Twort and
d’Herelle and investigations into phages have helped shape the modern understanding of
molecular biology. Phages are now considered to be the most abundant lifeform on earth, with
about 1031 individual phage particles in existence (84). While E. coli phages have often been at
the center of phage research, Bacillus phages have been well-studied. The first bacteriophage
isolated against B. anthracis was discovered in 1930 by Philip Cowles from raw sewage (85).
Bacillus phage discovery continued in the 1950’s when Elinor McCloy isolated a phage against
B. cereus strain W (86). McCloy tested the ability of phage W to infect many members of the B.
cereus group and found that it infected most of the B. anthracis strains tested but only a few of
the B. cereus strains and none of the other members of the group. Several years later, Brown and
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Cherry isolated a variant of phage W known as phage Gamma that was able to lyse every strain
of B. anthracis and none of the other B. cereus group strains tested (87). Because of this high
specificity, Brown and Cherry proposed that phage Gamma could be useful as a diagnostic tool
for anthrax infection. The Gamma phage lysis assay has since been a standard tool for anthrax
diagnostics (88).
Phages can be classified based
off of their morphology and the type of
genome they have. All Bacillus phages
currently identified have double
stranded DNA genomes and most are
members of the order Caudovirales
(89). These phages are characterized by
an icosahedral head with a tail (90).

Figure 1.9: Caudovirales Morphologies. The three families
within the order Caudovirales can be distinguished based on
their tails. Myoviridae is shown in green. Siphoviridae is
shown in red. Podoviridae is shown in blue

Caudovirales are further classified into families, the most common being Myoviridae,
Siphoviridae, and Podoviridae based on the characteristics of their tails (Fig. 1.9). Myoviridae
have long, contractile tails while Siphoviridae have long, non-contractile tails. Finally,
Podoviridae have short, non-contractile tails. Most Bacillus phages fall into the Myoviridae and
Siphoviridae families (89).
Phage-Based Technologies Used to Detect and Treat Anthrax
Interest in phage research has peaked in recent years due to the increasing number of
applications of phage-based technologies. Modifications to the Gamma phage detection assay
mentioned above have been used to detect the presence of B. anthracis in more complex
situations. Much of this work has been done by D. A. Schofield who created a bioluminescent
20

reporter phage by introducing the luxA and luxB genes of Vibrio harveyi into a non-coding
region of the Wβ genome, a close relative of phage Gamma (91). The Wβ::luxAB reporter phage
was capable of infecting both vegetative cells and germinating spores and generating a luciferase
signal within 16 minutes and 60 minutes of infection, respectively. Wβ::luxAB was also found to
be able to identify B. anthracis contamination in complex food matrices such as ground beef and
milk (92). This is useful as the food and dairy industry is considered a possible target for a
bioterrorism attack and gastrointestinal anthrax is a deadly form of infection. Finally, Wβ::luxAB
was used to determine antibiotic susceptibility on the premise that resistant strains of B.
anthracis would produce a brighter bioluminescent signal than those that were susceptible, as
more bacteria would be able to grow which thus results in the production of more bioluminescent
reporter phage (93). Overall, these studies show that Wβ::luxAB can be used in a variety of
clinical situations to both detect the presence of B. anthracis and determine its antibiotic
susceptibility which could greatly enhance the speed and quality of treatment. However, this
utility is limited to vegetative cells as an active metabolism is required for the production of the
luciferase genes.
The detection of spores using phages is more complicated as the bacterium is not actively
metabolizing at this point in its life cycle. Nevertheless, phage-based technology can be used in
the detection of B. anthracis spores. One of the most common ways to develop a spore detection
assay is through the use of a phage display screen to identify peptides that are capable of binding
to the spore surface. Phage display assays work by fusing peptide sequences with the coat protein
of the phage, allowing for the expression of the peptide on the phage’s surface (94). Libraries can
then be created with phages expressing many different peptides and screened by adding the
library to a plate onto which a protein of interest is fused (95). If the displayed protein binds to
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the protein of interest on the plate, the phage can be replicated and further studied for more
advanced binding interactions. Fragments of antibodies are often the peptides of choice in phage
display assays as these peptides can be easily generated and have high binding specificities and
affinities. One study was able to generate a single chain Fv antibody (scFv), composed of the
variable heavy and light chains bound together, that was capable of detecting only B. anthracis
spores and not those of other B. cereus group members (96). This was done by immunizing
BALB/c mice against the exosporium of B. anthracis spores, isolating and amplifying the cDNA
of the heavy and light chain regions, and creating a phage display library with the subsequent
sequences. The library was then screened against live spores. A similar method was used to
generate an antibody subunit capable of binding to BclA, a protein found on the surface of B.
anthracis spores (97). This anti-BclA antibody was then fused to β-galactosidase for use in
ELISA assays for spore detection. These technologies could provide a way for the rapid
detection and characterization of both vegetative B. anthracis cells and spores.
Phage based technologies can also be used in the treatment of anthrax infections.
Typically, antibiotics such as doxycycline, ciprofloxacin, and penicillin are used to treat anthrax
infections (98). These treatments are fairly successful, especially when used in conjunction with
an antitoxin. However, because B. anthracis has the potential to be used as a bioweapon, it’s
possible that a strain could be engineered that is resistant to common antibiotic treatments. While
no phage therapy is currently approved for use against anthrax infection, phages provide a
promising alternative to antibiotics as a result of their ability to specifically target and kill the
infecting bacteria. Additionally, phages are able to evolve along with their host, reducing the
possibility of the bacteria acquiring resistance. The use of phage to prevent infection in animal
models has been successful for a number of common bacterial infections including E. coli,
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Pseudomonas aeruginosa, Salmonella spp. and Staphylococcus aureus (99). The first attempt at
using phage therapy as a treatment against anthrax occurred in 1931 when mice were protected
from infection by mixing B. anthracis with phage before injecting the cocktail into the mice
(100). Since then, phage therapy development for anthrax treatment using whole phage hasn’t
yielded much success. Instead, focus has shifted to using a specific phage enzyme known has an
endolysin, or simply lysin. Lysins function by breaking apart the bonds of peptidoglycan that
make up the cell wall, thus causing a shift in osmotic pressure which causes the cell to lyse open
(101). Focus on Bacillus phage lysins has highlighted PlyG, encoded by Gamma phage. PlyG
was found to be highly effective at inducing cell lysis in every B. anthracis strain tested but not
against other members of the B. cereus group, besides one B. cereus strain (RSVF1) which was
already known to be susceptible to Gamma phage (102). In the same study, it was found that
mice injected with 1x106 RSVF1 colony forming units and then treated with PlyG fifteen
minutes post infection were protected from death nearly 70% of the time while the other 30%
survived significantly longer before succumbing to infection than their untreated counterparts.
PlyG was also found to be able to recognize and inactivate B. anthracis spores whether they
were germinating or not (103). While more research needs to be done to further evaluate the
effectiveness and safety of phage therapy against anthrax infection, early studies seem
promising.
Phage-based technologies can be used in a number of different situations. Phages can be
used not only to detect but also to treat bacterial infections. Further, enzymes and assays derived
from phages have led to the discovery of many other useful molecules and the advancement of
molecular biology in general. Thus, the continual discovery and analysis of novel phages is
important to continue to stay ahead in the fight against bacteria.
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Summary of Aims to Elucidate the Effects of R77Q and R36W
Because differences in experimental design in previous investigations into R77Q and
R36W have yielded conflicting results, we seek to obtain a clearer picture of what is occurring
during an infection with R77Q or R36W HIV-1 variants. Since previous studies have typically
used transfection of the vpr gene alone, or pseudotyped virus lacking the HIV-1 env gene (which
is also known to induce apoptosis), in our studies we are using whole, replication-competent
HIVNL4-3. Because cancerous T cell lines are not indicative of what occurs during natural HIV-1
infection, we will study the differences in apoptosis in infected primary CD4+ T cells.
Additionally, we will attempt to establish a humanized mouse model in order to study the effects
of Vpr on disease progression in vivo.
Summary of Aims to Characterize Novel Bacillus anthracis Phages
As novel phages are important for the advancement of anthrax detection and treatment,
we seek to characterize twelve novel B. anthracis phages in order to better understand their
genomic composition. We seek to identify novel gene products encoded by these phages that
influence the bacterial life cycle. We also seek to group these phages into phylogenetic clusters
with each other as well as investigate their relationship to previously published Bacillus phages.
The knowledge will be useful to better understand the dynamics of Bacillus phage relationships
with their host, as well as provide novel proteins that could potentially be useful in future gene
therapies or phage-based technologies.
Experimental Plan
Generation and Titering of HIV NL4-3 Stocks
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In order to study the effects of Vpr polymorphisms in vitro, viral stocks must be created.
This can be done transfecting Human Embryonic Kidney cells (HEK-293T) with previously
made molecular clones containing the full HIVNL4-3 genome with the appropriate Vpr mutation.
Four variants of the virus will be used including wild type (WT), R36W, R77Q, and a vpr
knockout (null). Transfection is be performed using the calcium phosphate method. Titering can
then occur by infecting Ghost cells with the stocks generated by the transfections. Ghost cells
harbor a plasmid encoding for GFP under the control of the LTR of HIV. Thus, actively infected
cells will produce GFP. Using the Tissue Culture Infectious Dose method, TCID50 units can be
calculated by determining which viral dilution results in 50% infected cells. Viral titers of 1x104
TCID50 units/mL will be considered sufficient for use.
Assessment of Apoptosis
In order to study the effects of Vpr polymorphisms on the induction of apoptosis, primary
CD4+ T cells are infected at a Multiplicity of Infection (MOI) of 0.01. At days three, five, and
seven post-infection, a sample of cells can be taken from each infection and analyzed for
apoptosis. This is done using the LIVE/DEAD Fixable Far Red Dead Cell stain kit
(FVD)(ThermoFisher) which functions by binding to free amines. When a cell has died, the
membrane becomes porous, allowing the dye to also bind to free amines within the cell, resulting
in an increase in the fluorescent signal. Additionally, annexin V conjugated to FITC is also used.
Annexin V binds to the phosphatidylserine which typically exists on the inner leaflet but gets
flipped to the outer leaflet while a cell is undergoing apoptosis. The resulting stained cells are
then analyzed by flow cytometry, with those cells that are annexin V single positive being
considered apoptotic while those that are FVD and annexin V double positive are considered
dead by necrosis.
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Primary CD4+ cells will be isolated from peripheral blood of HIV negative donors. First,
white blood cells will be separated from the red blood cells through a Ficoll-paque density
gradient. Then, CD4+ cells from the white cell layer will be isolated with a positive selection
cocktail. The cells are cultured in RPMI media supplemented with penicillin, streptomycin, and
newborn calf serum. Infection occurs at least 1 day post isolation.
The Production of Humanized Mice
As HIV-1 can only infect humans, adequate animal models for the study of disease
progression are difficult to come by. One solution is to use transgenic mice whose immune
system has been replaced to reflect more of that of a human, otherwise known as humanized
mice (104). In order to generate humanized mice, CD34+ hematopoietic stem cells are first
isolated from human umbilical cord blood. This is done by first isolating white blood cells using
a density gradient, then using a positive selection cocktail (STEMcell) to further isolate the
CD34+ cells. The isolated cells are then allowed to culture in serum free IMDM for 48 hours.
BALB/c Rag2-/- γC-/- pups between one and five days old are prepped for engraftment by gamma
irradiation. Then, the isolated CD34+ cells are engrafted into the pups by injection into the liver.
The pups are returned to their mothers and allowed to grow. After 8 weeks, the mice are then
screened for successful engraftment. This is done by collecting peripheral blood and staining it
with fluorochrome conjugated antibodies against human CD45 and mouse CD45, followed by
analysis by flow cytometry. A successful engraftment is considered as 10% human CD45+ cell
population.
Characterization of Novel B. anthracis Phage Genomes
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In order to use a novel bacteriophage in a phage therapy cocktail or in other phage-based
technologies, it’s important to first analyze its genome for any potentially useful or hazardous
genes. For example, some phages may harbor antibiotic resistance genes that would not be
desirable to introduce in a clinical infection. To assess the genes present in a phage genome, the
DNA sequence is imported into a program called DNA Master. DNA master will then predict
where genes are most likely present throughout the genome. While this automated annotation is
fairly accurate, it is important that the research goes through and verifies by hand that each gene
call made by the program is accurate, aided by GeneMarkS which predicts coding potential
based on codon bias. During the annotation process, the researcher can predict the function of
each gene using the Basic Local Alignment Search Tool of proteins (BLASTp). When an amino
acid sequence is entered into a BLASTp search, BLAST will compare it with the amino acid
sequences of all currently published proteins looking for similarities. If the search returns
proteins of known function, it can be assumed that the novel protein will display a similar
function. In addition to BLASTp, Phyre2 can also be used to predict the function of a protein.
Phyre2 attempts to predict the structure of the imported amino acid sequence and compares that
structure to other proteins whose structure and function has already been described. In this way,
it is possible to annotate a genome and assign potential functions to many of the newly
discovered genes.
In addition to genomic annotation, it is also important to identify how phages are related
to one another. This can be done using a dot plot created by Gepard. Gepard compares the
sequences of either the nucleotides or amino acids entered into it and generates a dot wherever
the sequences are the same. In this way, a dot plot can highlight areas of similarity between
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genomes and indicate clusters of related phages. This can then be verified by the creation of a
phylogenetic tree using a program such as Kalign.
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CHAPTER II: THE EFFECTS OF Vpr POLYMORPHIMS IN PRIMARY T CELLS AND THE
CREATION OF A HUMANIZED MOUSE MODEL
Introduction
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of acquired
immunodeficiency syndrome (AIDS). The first diagnosis of AIDS occurred in 1981 following an
outbreak of rare opportunistic infections and cancers (14). HIV-1 was then isolated and identified
as the disease-causing agent in 1983 (15). Since then, HIV-1 has been the subject of intense
study in order to better understand it’s life cycle and pathogenicity.
As a member of the Retroviridae family, HIV-1 has a complex life cycle that involves
reverse transcription of its RNA genome into DNA and subsequent integration into the host’s
genome (16). One protein that assists in the viral life cycle is viral protein R (Vpr). Although a
small protein, Vpr is involved in a number of different viral functions including immune evasion,
cell cycle arrest, the transport of the pre-integration complex into the nucleus, and apoptosis (40,
42, 46, 47). Two polymorphisms to the Vpr protein have been associated with differences in
disease progression. The first polymorphism of note is a change of the arginine at position 77 to
glutamine (R77Q). This R77Q polymorphism has been associated with long-term nonprogression (LTNP) where patients are able to maintain their CD4+ T cell levels, and thus avoid
AIDS, for much longer than is typical (74, 75). On the other hand, a change of the arginine at
position 36 to a tryptophan (R36W) results in rapid progression (RP) (76). RP patients
experience a much faster drop in their CD4+ T cell levels, developing AIDS much more quickly.
Recently, our lab has undertaken a study to better understand how these two
polymorphisms result in such drastic differences in disease progression. Using the HUT78 T cell
line, we sought to quantify the effects of infection by viruses harboring the R77Q, R36W, and
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Vpr knockout (Null) polymorphisms when compared to wild-type infection (WT). It was shown
that R36W results in increased viral load and reproduction as measured by Q-RT-PCR and
staining for the p24 capsid protein. Additionally, R36W was found to induce cell death at greater
rates. On the other hand, R77Q was found to induce increased cell cycle arrest in the G2 phase
and increased cell death via apoptosis. These findings led us to believe that the RP seen by
R36W is a result of increased inflammation induced by the necrotic nature R36W induced cell
death and the increased viral replication. However, the apoptosis induced by R77Q is noninflammatory, resulting in fewer activated T-cells being recruited to the site of infection, and
thus fewer targets for the virus to infect. This leads to R77Q producing the LTNP phenotype.
However, these hypotheses cannot be confirmed by testing in cell culture alone. Thus, we
sought to further this investigation by repeating the studies in more representative model
systems. As HUT78 cells are a cancerous line, it’s likely that they don’t respond to infection in
the same way as primary T cells. To overcome this, we wanted to repeat the apoptosis studies
using primary CD4+ T cells. Further, in vitro systems are limited as they can’t explain what
happens during infection of a whole body. As HIV-1 only infects human immune cells, it is
difficult to find an effective in vivo model. Fortunately, humanized mice, engrafted with human
hematopoietic stem cells, offer a good experimental system to study in vivo HIV-1 infection
(104-106). As our lab hadn’t produced humanized mice in several years, we sought to begin their
production once again and in order to shed more light on the RP and LTNP phenotypes. The
results in this chapter represent our efforts to further these two projects.
Results
Virus Stock Preparation and Titering

30

In order to begin this project, fresh stocks of each virus had to be generated as there were
none left over from the previous experiments. Four different HIVNL4-3 plasmid clones each
harboring a different mutation that produced the WT, R36W, R77Q, and Null Vpr’s had been
made previously through site-directed mutagenesis. In order to reduce the risk of using all the
remaining molecular clone stocks, we began by transforming Escherichia coli Stbl3 with each
plasmid. Other transformation competent E. coli strains cannot be used because the long terminal
repeats (LTRs) at the end of the HIV-1 genome are easily cut by the cell’s recombination
machinery, thus losing the entire HIV-1 portion of the plasmid. Stbl3 cells, however, cannot
perform recombination, and thus serves as an effective host for transforming lentivirus-based
plasmids containing LTRs (107). The transformation of the E. coli was done via the heat shock
method in which the cells were incubated with the plasmid DNA on ice for 30 minutes before
submersion in a 42°C heat bath for 1 ½ minutes followed by a return to the ice for 2 minutes.
Fresh LB media was then added to the cells which were allowed to rest for 45 minutes in a 37°C
shaking incubator before being plated onto LB agar plates supplemented with ampicillin. The
first issues came when trying to determine the appropriate concentration of ampicillin to add to
the plates in order to properly select for transformed cells. The proposed 100 μg/ml concentration
resulted in absolutely no growth after 48 hours, even in the positive control which was
transformed using the pUC-19 plasmid. The next concentration that was tested was 20 μg/ml
which resulted in a lawn of growth on all plates. 50 μg/ml proved to be the ideal concentration of
ampicillin which resulted in distinct, individual bacterial colonies. A single colony from each
plate (WT, R36W, R77Q, and Null) was then picked using a sterile loop and inoculated into LB
media with the same concentration of ampicillin and grown over night.
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Next, plasmid DNA was isolated from the overnight cultures using the E.Z.N.A Plasmid
DNA Extraction kit from Omega Bio-Tek. Despite the ease of a DNA extraction kit, high
enough concentrations of DNA were not obtained from the first several attempts resulting in
DNA concentrations of less than 100 ng/μl. Eventually we found that by allowing the
transformed cells to grow for 2 days before plasmid isolation, instead of simply overnight, higher
DNA concentrations could be reached. Higher concentrations were also obtained when the
Sorvall high speed centrifuge in the RIC was used as the original centrifuge in our lab could not
reach the high speeds required in the protocol. This combination of adaptations eventually
allowed us to reach a concentration of between 600 and 800 ng/μl which was sufficient for the
next step of virus stock production. As a quality control step, newly produced plasmids were run
though a gel to ensure that they appeared at the expected length (15 kb). We quickly learned,
however, that circular plasmids do not move as expected through a gel (Fig. 2.1A). After
linearizing the
A)

123456

B)

12 3 4 5 6 7 8 9 10 11

plasmid using the
Eco-RI restriction
enzyme, bands
appeared at the
expected 15 kb

Figure 2.1: Quality Control Gel Electrophoresis. After the molecular clones were made
and isolated, they were run on a 1% agarose gel to ensure that the plasmid was isolated
without any other contaminating DNA. A) Circular plasmids do not run uniformly down an
agarose gel. Lane 1 is the DNA ladder. Lane 2 was intentionally left blank. Lane 3,4,5,
and 6 are WT, Null, R36W, and R77Q plasmids, respectively. B) Linearizing the plasmid
by cutting with a restriction enzyme allows the DNA to run uniformly. The new isolated
DNA (Lanes 8-11) matches the expected length (15 kb) as well as the plasmids
previously made (Lanes 3-6). Lane1 is the DNA ladder. Lanes 2 and 7 were intentionally
left blank. Lanes 3 and 8 are WT plasmid. Lanes 4 and 9 are Null plasmids. Lanes 5 and
10 are R36W plasmids. Lanes 6 and 11 are R77Q plasmids

height. The banding
of the newly
prepared plasmids
was at the same
height as the
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plasmids previously prepared, indicating that the appropriate plasmid had been selected for and
that there was no contamination (Fig. 2.1B).
After the plasmids where made, the next step in producing new viral stocks was to
transfect HEK-293T cells with the newly produced plasmids. Again, we began by using an
established protocol provided by the AIDS Reagent Program (now HIV Reagent Program) that
failed to yield the desired results. This method involved mixing the DNA with calcium chloride
and HEPES buffered saline (HBS) before adding the solution to the cells and allowing them to
grow for 48 hours. The only intervention to the cells was to change the media at 12 to 16 hours
post-transfection. When this protocol was performed exactly as written, the viral stocks resulted
in very low titers, in the 101-102 TCID50 units/ml range. So, an alternative transfection protocol
resulting in higher titers was sought. Two candidates arose; a similar calcium phosphate-based
protocol that additionally included a glycerol shock, and a lipofectamine-based one. While the
exact mechanism of how the calcium phosphate method works is unknown, it's generally
believed that the calcium interacts with the phosphate in HBS forming a positively charged
calcium phosphate molecule that then interacts with the negatively charged DNA. The
DNA/calcium phosphate complex then binds to the cell membrane and gets taken up by the cell
through either endocytosis or phagocytosis (108, 109). The addition of a glycerol shock after
transfection by the calcium phosphate method often increases the yield by aiding in endosomal
release of the DNA (110), although the exact mechanism is still unknown. The lipofectamine
method functions similarly to the calcium phosphate method where the positively charged lipids
complex with the DNA before fusing with the cell membrane and releasing the DNA into the cell
(108). It has been suggested that lipofectamine also assists the DNA to enter the nucleus of nondividing cells, although again the mechanism isn’t clear (111). These three protocols (the
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calcium phosphate method, calcium phosphate plus glycerol shock, and lipofectamine) were
tested head-to-head to see which protocol resulted in the highest yield. Surprisingly, the original
protocol produced the highest titers, so we began seeking ways to optimize it. When harvesting
the virus stocks at 48 hours post-transfection, the media on the cells was often very
orange/yellow, indicating a low pH. HIV-1 is very sensitive to changes in pH and loses its ability
to infect at more acidic pH, which could be the cause of the low yield (112). In order to buffer
the pH, we began adding fresh media, about 5 ml, to the cells at 36 hours post-transfection, 12
hours before harvesting. Additionally, a former graduate student suggested changing the media at
9 hours post-transfection, instead of the protocol dictated 12-16 hours. This combination of
adjustments increased the yield of the transfection protocols to a usable titer of at least 104
TCID50 units/ml.
Once the stocks were made, they needed to be titered. Many viruses can be titered by
plaque assay where the amount of virus is correlated to the number of plaques found on a plate,
multiplied by the dilution factor. HIV infection, however, does not result in plaques. Therefore,
titering of HIV is done by finding the dilution of virus that infects 50% of the tissue culture, in
other words the tissue culture infectious dose of 50% (TCID50). GHOST(3) cells are often used
to titer HIV as they have been engineered to produce the CD4 receptor, the CCR5 and CXCR4
coreceptors, and a plasmid that encodes GFP under the control of a LTR promoter (113). Thus,
when GHOST(3) cells are infected by HIV, they fluoresce green, and the titer can be determined
by finding the virus dilution which causes half of the cells to fluoresce. More specifically, serial
dilutions of the virus stocks were used to infected 5 wells of GHOST(3) cells each. Then, using a
fluorescent microscope, the wells that were producing GFP were identified and counted as
positive while the wells that didn’t produce GFP were counted as negative. The dilution that

34

produced half positive and half negative wells was then used to calculate the TCID50. As using
the fluorescent microscope was time and labor intensive, as well prone to user error, analyzing
the results via flow cytometry provided a beneficial alternative. The flow cytometry analysis
resulted in more accurate counting of the number of cells that were producing GFP while being
able to disregard the cells that were auto-fluorescing.
The process of producing the plasmid, optimizing the transfection protocol, and titering
the cells took over a year. But after the many months of hard work, viral stocks of all four
variants that were at or above a titer of 104 were produced, well suited for the infection assays
that would be done at a multiplicity of infection (MOI) of 0.01.
Learning the Technique of Flow Cytometry and Practicing the Apoptosis Staining Protocol
Once the virus stocks were produced at high enough titers, it was time to begin the
process of trying to replicate the results of the HUT78 infections in the primary cells. Most of the
analysis of these experiments was done using flow cytometry. Flow cytometry works by passing
cells one by one in front of a laser and detecting the characteristics of the light that gets reflected
off the cell (114). Light that gets scattered forward (forward scatter or FSC) is indicative of the
cell size while light that gets scattered at a 90° angle from the laser (side scatter or SSC) is
indicative of a cell’s complexity or granularity. Additionally, the cells can be stained with
fluorescent antibodies or dyes which get excited by the laser as the cell passes through the beam.
Thus, a cell that fluoresces when it passes in front of the laser is expressing that protein or
condition that was labeled by the dye or antibody. The BYU RIC facility offers two choices of
flow cytometer available for use: the BD Accuri and the Beckman Coulter Cytoflex. The Accuri
offers ease of use but only provides four fluorescent channels with two lasers while the Cytoflex
requires more training but offers 13 channels with four lasers. Because the Cytoflex provided
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more possible combinations of fluorescent markers, it was used exclusively during the following
course of experimentation.
When running a flow cytometry experiment, it’s important to understand what is
occurring biologically which results in the different staining. A common way to study apoptosis
through flow cytometry is by staining with Annexin V and propidium iodide (PI) (115). Annexin
V binds to phosphatidylserine while PI binds to DNA. When a cell is undergoing apoptosis, the
phosphatidylserine, which normally exists on the inner leaflet of the cell membrane, gets flipped
to the outer leaflet, where the Annexin V is able to bind to it. Meanwhile, when a cell is dying,
but not apoptotic, pores form in the membrane which allows PI to enter and stain the DNA.
Annexin V is also able to enter the pores and will bind to the phosphatidylserine on the inner
leaflet. Thus, only those cells that stain positive for Annexin V but negative for PI are considered
apoptotic, while those cells that stain positive for both are considered dead or necrotic. However,
because our cells would be infected by HIV-1, they needed to be fixed with paraformaldehyde
before analyzing the staining with flow cytometry. Unfortunately, PI staining cannot be fixed as
the fixing process interferes with the binding of PI to the DNA (116). Thus, we had to utilize a
different live/dead stain. As an alternative, we chose the LIVE/DEAD Fixable Far Red Dead Cell
stain kit (FVD) (ThermoFisher) which binds to free amine groups. Live cells exclude FVD
binding to just amine group on the cell surface while the pores of dead cells allow the dye to bind
amine groups found both outside and inside the cell (117). Thus, dead cells result in a higher
fluorescent intensity than live cells. This method allowed us to determine the apoptotic cells in
the same way as the PI/Annexin V stain.
The flow cytometry experiments began by attempting to replicate the results obtained
previously in HUT78 cells. This would allow us to gain experience with both the staining
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protocol and the flow analysis while generating expected results to verify that everything was
done properly. HUT78 cells were infected with an MOI of 0.01 with all four virus variants and
samples were taken at days 3, 5, and 7 post infection. Our first concern when running this
protocol was that if the staining was done three separate times, samples stained on one day may
accidentally receive more stain than those of other days, thus resulting in an increase in
fluorescence that wasn’t biologically significant. To overcome this, we fixed each sample on the
day they were drawn and then later stain all the samples at the same time. However, this didn’t
work as fixing with paraformaldehyde results in cellular proteins and components changing
shape, and thus not binding properly to the stains. Thus, the first two attempts at replicating the
HUT78 experiments failed to yield usable data.
Next, a good apoptotic biological control was needed in order to definitively tell when a
virus variant was inducing apoptosis. Dimethyl sulfoxide (DMSO) is often used to induce
Heat killed

DMSO killed
Q2 – 27.41%

Q4 – 11.43%

Q3 – 61.11%

Q1 – 0.50%

Q2 – 95.35%

Q4 – 3.87%

Q3 – 0.28%

FVD

FVD

Q1 – 0.06%

Annexin V

Annexin V

Figure 2.2: DMSO Serves as a Good Biological Apoptotic Control. Healthy HUT78 cells were either treated
with 2.5% DMSO for 48 hours or 60°C for 20 minutes to induce cell death. The cells were then stained with
Annexin V and FVD and the results were analyzed by flow cytometry. DMSO treatment resulted in 61%
apoptosis (blue), 27% death (red) and 11% healthy (green). Heat treatment resulted in mostly cell death
(95%). The results of the 75% EtOH are not shown because of Annexin V was unable to bind to those cells.
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apoptosis in cells, so we began to test what concentration of DMSO would be best to use as a
biological control (118). HUT78 cells were cultured in concentrations of 0.5%, 1%, 2.5%, 5%,
and 10% DMSO and the number of dead cells were counted after 48 hours by staining with
trypan blue using a hemacytometer. We determined that 2.5% DMSO resulted in about 50%
dead cells. Other potential apoptosis inducers are ethanol (EtOH) and heat. Therefore, healthy
cells were exposed to 70% EtOH and 60°C for 20 minutes before being stained with FVD and
Annexin V. DMSO-treated cells were also stained in the same manner. This experiment showed
that 2.5% DMSO was the ideal biological apoptosis control as about 60% of the cells were
apoptotic while 27% were dead and 11% were healthy (Fig. 2.2). Killing the cells with heat
resulted in 95% cell death. The treatment with EtOH also resulted in more than 90% FVD
positive cells, indicating cell death, however the Annexin V was unable to bind to the cells.
It was during this experimenting that we began to worry that the HUT78 stocks had
become contaminated, as two distinct populations were appearing on the FCS/SSC graphs.
Cultures of HUT78 cells were grown from various stocks to determine which stocks were
contaminated and when the contamination occurred. Interestingly, the FCS/SSC profiles of all
the stocks tested revealed the same two distinct populations. Even the data from the previous
HUT78 infection assays showed the two populations. After studying the data, we realized that
the two populations correlated with the healthy and dead populations on the FVD/Annexin V
graph. The FCS/SSC profile of dead cells is different than that of healthy cells, as a dead cell
well show up smaller with increased side scattering (115). Therefore, the cultures weren’t
contaminated and were actually appearing as expected.
The Induction of Apoptosis in Primary Cells
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After all this troubleshooting, we determined that our time was best spent testing the
effects of the Vpr mutants in primary cells instead of simply recreating the results in the HUT78
cell. The first step in doing so was to isolate primary cells from willing donors in the lab. 40-50
ml of blood was drawn from each donor, typically resulting in 20x106 - 30x106 CD4+ cells. The
isolation protocol occurs as follows. First, the white and red blood cells are separated using a
Ficoll-paque density gradient. The white cell layer is selected while the rest is discarded. CD4+
cells are then positively selected using the EasySep Human CD4 Positive Selection Kit II
(Stemcell). This kit functions by binding anti-CD4 antibodies to cells that express CD4. Then
magnetic particles are added which bind to the Fc region of the antibodies. The tube is then
placed in a magnet for several minutes and the contents are poured out while the tube is still in
the magnet. In so doing, any cell expressing CD4 will stick to the walls of the tube while all
other cells are discarded. This step is repeated several times to ensure that any CD4- cells are
washed out. The primary CD4+ cells are then cultured in RPMI supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin for one day after isolation before being used
for any experiments. To determine what percentage of the isolated cells were CD4+ T cells
versus other CD4 expressing cells like macrophages, the isolated cells were stained with antiCD45 antibody (the pan-leukocyte marker), anti-CD3 antibody (the pan-T cell marker), and antiCD4 antibody. This staining regimen would show which CD4+ cells were T cells (CD45 and
CD3 double positive), and which were not (CD45 positive, CD3 negative). We found that most
of the isolated cells were CD4+ T cells. We also found by trypan blue staining that the primary
cells were able to be cultured and remain viable for up to 8 days post isolation.
With this knowledge in mind, we began to test the effects of infection with each Vpr
variant in primary cells. Primary cells were infected one day after extraction with an MOI of
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0.01. Uninfected cells were mock infected with RPMI and polybrene. Then at days 3, 5, and 7
post-infection, a sample of cells was taken from each infection and stained them with FVD and
Annexin V. Having learned from the previous practices in the HUT78 cells, the staining was
done on the day of the sampling instead of all together. Interestingly, this experiment showed
that there was a statistically significant increase in apoptotic cells after infection with the R77Q
variant and the Null variant when compared to the uninfected control and WT (Fig. 2.3A). This
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Figure 2.3: Infection of Primary Cells Over 7 Days Shows High
Background Cell Death. Primary CD4+ T cells were infected at an MOI
of 0.01 and samples were stained for FVD and Annexin V at days 3, 5,
and 7 post infection. A) Average percent apoptotic cells. Infection with
R77Q and Vpr Null viruses results in a statistically significant increase
in the percentage of apoptotic cells at day 5. * Indicates p-value ≤
0.05. ** Indicates p-value ≤0.01. B) Average percent dead cells.
Uninfected (UI) cells have a high amount of background cell death.
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the three days (Fig. 2.3B).
Wondering if the primary
cells simply weren’t viable for the
full length of the experiment, they
were stained at day 1 and 3 post

infection instead of the full seven-day assay. The high amount of background cell death could
partially be explained by the fact that HIV-1 infection is inefficient in resting primary cells,
leading to abortive infection and cell death (119). Thus, the cells were also stained for
intracellular p24 to determine if the virus was replicating. However, after analyzing the day 1
staining, there was still a large amount of background cell death. Every sample tested, whether
infected or not, had 90% or more dead or apoptotic cells. Noting this result, we decided not to
stain for FVD and Annexin V at day 3. Interestingly, all of the cells in the unstained and single
stained controls were healthy. Typically, these cells would have been treated with 2.5% DMSO,
however, we had failed to prepare properly for this particular experiment. Therefore, they were
taken directly out of the culture of the remaining primary cells that hadn’t been used for the
infections.
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Figure 2.4: Infection of Primary Cells Produces
Detectable p24 After 3 Days. Primary CD4+ T
cells were infected with each virus and were
stained for p24 production 1- and 3-days post
infection. P24 levels in all infected samples were
not statistically different than the uninfected
control (UI) after 1 day of infection. However, all
viruses produced increased p24 levels after 3
days. Infection with the R77Q variant produced
the most p24. * Indicates p-value ≤ 0.05

determine the degree to which the virus was
replicating. There was very little p24 production at
1-day post infection (Fig. 2.4). This was expected
as virion production usually begins around 24
hours post infection (25). After 3 days, however,
all four virus variants were producing detectable
p24 levels. Interestingly, there was an increase in

p24 production by R77Q with nearly 30% of cells staining positive for p24 compared to less than
10% of cells for all other conditions. This difference was statistically significant compared to
Null (p-value = 0.054) and was almost significant compared to WT (p value = 0.060).
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Figure 2.5: Polybrene has a Toxic Effect on Primary Cells.
HUT78 and primary cells were mock infected with RPMI and
polybrene at the concentrations indicated and stained with
FVD and Annexin V after 1 day. A new stock of polybrene
was made fresh (new) to compare to the stock that had been
used in previous experiments (old). 200 ug/ml caused a
significantly increased amount of cell death in primary cells.
Graph represents % of cells that were dead (FVD+ and
Annexin V+). * Indicates p-value ≤0.05, ** indicates p-value
≤0.01.

efficiency of infection (120). However,
polybrene has been found to be toxic at
certain concentrations in certain cell types
(121). During the HUT78 infections, a
concentration of 20 μg/ml of polybrene

was used. We suspected that primary cells were much more susceptible to the cytotoxic effects
of polybrene than the HUT78 cells. Therefore, different concentrations of polybrene were made
to determine how they affected both HUT78 and primary cells. Concentrations of 0 μg/ml, 5
μg/ml, 10 μg/ml, and 20 μg/ml from both the old and a new polybrene stock were used to mock
infect both cell types (Fig. 2.5). It was at this point that we realized that the wrong dilution of the
polybrene stock had been used throughout all the previous experiments. The stock was at 1000x
(20mg/ml). However, it was only diluted down 1:100, resulting in a working concentration of
200 μg/ml of polybrene instead of the intended 20 μg/ml. We found that 32% of the primary
cells were dead after mock infection with 200 μg/ml of polybrene. Interestingly, there was not a
significant difference in cell death among the HUT78 cells, regardless of the concentration of
polybrene used. In the primary cells, all other concentrations produced a background amount of
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cell death of less than 10% which was not statistically different than the cells that received no
polybrene. Although not statistically significant, 20 μg/ml of polybrene using the old stock
produced the least amount of cell death in primary cells (4.1%).
Now knowing that adding too much polybrene would result in large amounts of cell
death, we attempted again the experiment to see how each Vpr variant affected apoptosis and cell
death. This time the cells were infected with 10 μg/ml of polybrene at the standard MOI of 0.01.
At days 2 and 3 post infection, the cells were again stained with FVD and Annexin V. The
analysis of the samples at day 2 resulted in a large
distribution of data resulting in large standard
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compared to the uninfected control. None of the
data was significant when compared to the WT
virus, as that data had the largest standard error. In
addition to inducing less apoptosis, infection with
the R77Q variant resulted in less cell death when
compared to the Null and the R36W variants (pvalues of 0.03 and 0.004 respectively) (Fig. 2.6B).
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Figure 2.6: R77Q and R36W Produce Less Cell Death
and Apoptosis at 3 Days Post Infection. Primary CD4+
cells were infected at MOI of 0.01 using 10 μg/ml of
polybrene. A) Average percent apoptotic cells. At 3
days post infection, there was an increase in apoptosis
in samples infected by the Null variant. Infection by
R36W and R77Q resulted in less apoptosis compared
to uninfected (UI) and Null. B) Average percent dead
cells. Infection by the R77Q results in a decrease in
cell death when compared to all other samples. *
Indicates p-values ≤ 0.05, ** indicates p-values ≤ 0.01.

This difference was almost significant compared to the uninfected and WT (p-values of 0.056
and 0.055 respectively). The differences seen in this experiment compared to the 7-day assay is
most likely due to the lower concentration of polybrene used here which resulted in less
background death. However, both experiments resulted in an increase in apoptosis induced by
infection with the Vpr Null virus.
Generation of Humanized Mouse Model
In addition to determining the effects of the Vpr polymorphisms in primary cells, we next
wanted to test how they would affect disease progression in an in vivo model. The gold standard
animal model for studying HIV infection and AIDS progression are non-human primates (NHP).
However, the high cost of NHP research is often a limiting factor. Additionally, only certain
NHP’s are susceptible to HIV-1 and most don’t progress to AIDS (122). Infection of NHPs with
simian immunodeficiency viruses (SIV), a group of lentiviruses closely related to HIV-1 and -2,
provides a good model for studying disease progression and immune response. However, these
lentiviruses encode an additional accessory protein, Vpx, that carries out similar functions as
Vpr, including the induction of apoptosis (123, 124). Thus, an attempt to study the effects of Vpr
polymorphisms using an SIV model could be hindered by the activity of Vpx. In contrast to the
high cost of experimentation with NHPs, mice provide a cheap and efficient way to study many
human diseases as their immune system is quite similar to that of humans. While mice are not
readily infected by HIV-1, transgenic mice that are capable of producing human immune cells
provide a good solution. These humanized mice provide a good model when studying long term
disease progression (106).
The process of creating a humanized mouse begins with isolating hematopoietic stem
cells from human umbilical cord blood (104). This is done in a very similar way as the extraction
44

of primary CD4+ cells discussed above. The EasySep Human Cord Blood CD34 Positive
Selection Kit II (Stemcell) includes antibodies specific to CD34, the hematopoietic stem cell
marker. Once the cells are isolated, they are cultured in IMDM media supplemented with 10%
FBS, 1% pen/strep, and 10 ng/ml each of SCF, IL-3, and IL-6. After two days of culturing, the
cells are injected into the livers of mouse pups between 1-5 days old. BALB/c Rag2-/- γc-/- mice
are used as these two knockout mutations limit the ability of the mice to produce their own
functioning immune cells. Before engraftment, the pups are prepared by exposure to gamma
irradiation. After the CD34+ cells are engrafted, the pups are returned to their mothers and
allowed to grow normally. Eight weeks after the injection of the cells, the mice are screened for
successful engraftment by drawing peripheral blood from the tail. The white blood cells are then
isolated using a red blood cell lysis buffer and stained using anti-human CD45 and anti-mouse
CD45 antibodies. Chronic HIV-1 infection can occur with as low as 10% human CD45+
populations, so that is the measurement used to determine successful engraftment.
After performing this protocol several times and getting mice with less than 1%
engraftment, we began to troubleshoot to identify where the problem was occurring. We first
noticed was that a low number of CD34+ cells were being cultured after each isolation. This
indicated that cells were most likely being lost at some stage of the isolation protocol. To
determine where the cells were being lost, samples were taken at each step including the red
blood cell layer, the white blood cell layer, and the plasma layer of the ficoll separation, and each
wash step with the magnet. These samples were stained with anti-CD45 and anti-CD34
antibodies and analyzed by flow cytometry. There were no CD34+ cells in the red blood cell
layer and the concentration of CD34+/CD45+ cells increased with each wash step, indicating
that our protocol was working as expected. We next suspected that the low number of isolated
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cells was due to receiving small amounts of umbilical cord blood from our collaborator at the
University of Utah Hospital. They typically gave us bags of blood that measured between 85-110
ml. However, upon investigating the collection bags, we learned that they already contained 65
ml of anti-coagulant. Thus, only about 20-45 ml of the total volume was actually umbilical cord
blood. Therefore, we requested that a different collection bag be used in order to receive more
blood. Meanwhile, we began to isolate CD34 cells only from the bags that gave more than 95 ml
of blood to ensure a sufficient volume of blood was used. These measures, in addition to more
practice handling the isolation protocol, allowed us to start isolating higher concretions of
CD34+ cells.
Early in the fall, CD34+ cells were isolated from a bag of umbilical cord blood and were
then used to engraft pups two days later. Unfortunately,

Mouse CD45

setbacks and poor coordination between lab members
resulted in the mice not being screened at the eight-week
mark but rather several months later. When the mice
were finally screened in early February, one mouse,
mouse number #69, had 23.6% human CD45+ cells
Human CD45

Figure 2.7: A Successfully Humanized
Mouse. BALB/c Rag2-/- γc-/- pups were
engrafted intrahepatically with human
CD34+ hematopoietic stem cells.
Peripheral blood was drawn and stained
with anti-mouse CD45 and anti-human
CD45 antibodies. This mouse reperesents
a successful engraftment with ≥ 10%
Human CD45+ cells. Numbers in
quadrants represent the % of total cells
that pertain to that quadrant.

(Fig. 2.7). This was the highest percentage of human
CD45+ cells that we had seen to date and the only
successfully humanized mouse. However, due to the five
months between engraftment and screening, it was
unclear what resulted in the success. Further, our
collaborators supplying the umbilical cord ended the

partnership, so we were unable reproduce the results. With only one mouse successfully
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humanized, we were unable to perform infections to study Vpr in vivo, however the stage was set
for the lab to be able to pursue this course of investigation in the future.
Discussion
Although the results presented herein are preliminary, they pose interesting implications
on the role of Vpr polymorphisms on the induction of apoptosis. The ability of R77Q to increase
or decrease the induction of apoptosis has been greatly debated. Much of Vpr’s ability to induce
G2 arrest and apoptosis relies on its C-terminal domain. The interaction of Vpr with DCAF1 uses
the N-terminal domain and the third α-helix (125). Further, Vpr binds to ANT to induce
mitochondrial permeability through two H(S/F)RIG motifs in the c-terminal domain (71, 126).
R77 is included in both the third α-helix and one H(S/F)RIG motif. Thus, a change of the
arginine at position 77 to a glutamine could hinder the ability of Vpr to bind to both DCAF1 and
ANT, affecting its ability to induce apoptosis. However, neither of these interactions include
R36, as it resides between the first and second α-helices. Thus, more research is needed to better
understand the mechanism behind R36W’s effect on cell death.
Above, we have shown that infection of primary cells with virus containing the R77Q
polymorphism results in less apoptosis. However, in our previous study in HUT78 cells, we
showed that R77Q results in increased apoptosis. Further, in the 2002 Lum et al. paper where
R77Q was first identified as contributing to the LTNP phenotype, they showed that R77Q
induces less apoptosis as measured by Annexin V/PI stain, caspase activation, and loss of
mitochondrial membrane integrity (Δψm), a measure of ANT activity (74). Additionally, in a
2009 study, Jacquot et al. showed that R77Q is associated with increased apoptosis and that the
polymorphism does not affect the ability of Vpr to bind to DCAF1. (77). It is currently unclear
why these studies have resulted in such drastically different results. However, one explanation
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could be due to experimental design. The Jacquot et al. study introduced the Vpr polymorphisms
via transfection in HPB-ALL T cells whereas the Lum et al. study used VSV-G pseudotyped
virus to introduce the Vpr variants into Jurkat T cells. These two methods are limited to
observing the role of Vpr alone. On the other hand, our studies utilized full, replication
competent HIV-1, allowing us to study Vpr in the context of infection including other viral and
cellular factors. This more closely mimics what would happen during an actual clinical infection.
Thus, the only difference in our two studies where the type of cell used, primary cells verse
cancerous secondary cell lines.
Infection of resting primary cells by HIV-1 is much less efficient than activated primary
cells. Blocks to infection of resting primary cells occur at many points of the viral life cycle
including attachment and entry, nuclear transport and integration, and viral budding; however,
the main block occurs at reverse transcription (127-129). This inability to complete reverse
transcription leads to abortive infection and apoptosis (119). However, the induction of G2 cell
cycle arrest seems to enhance the virus’s ability to complete reverse transcription as well as
enhanced integration and transcription (52, 130). This could explain the differences we’ve seen
between the effects of R77Q in HUT78 cells verses primary cells. In HUT78 cells, R77Q
induced increased G2 arrest and as a result, increased apoptosis. However, if R77Q also
increases G2 arrest in primary cells, this arrest would result in enhanced reverse transcription,
leading to less abortive infection and less apoptosis, as we saw. Additionally, the enhanced viral
replication caused by G2 arrest would explain the increase in p24 expression by the R77Q
variant. Further, this would explain how the Vpr null variant resulted in increased apoptosis in
primary cells but not a significant difference in HUT78’s, as Vpr is necessary to induce G2
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arrest. If G2 arrest isn’t achieved, a build-up of incomplete reverse transcripts will occur,
resulting in increased abortive infection and apoptosis.
Another interesting finding in our study was the difference in susceptibility to polybrene
of primary cells compared to HUT78 cells. Polybrene has long been known to be toxic at certain
concentrations in certain cell types, however the exact mechanism of this toxicity is unknown
(121). We saw this toxicity when comparing the results of figure 2 to those of figure 5. One
study found that in neuronal cells, polybrene increases the influx of Ca2+ into the cell resulting in
mitochondrial degradation and apoptosis (131). As a cancerous cell line, HUT78 cells express a
number of different proteins and transcription factors that may aid in their resistance to
apoptosis. One such transcription factor that is constitutively expressed in HUT78 cells is NF-κB
(132). Constitutive expression of NF-κB has been shown to confer resistance to both
mitochondrially induced and extrinsically induced apoptosis (133). As primary cells do not
overly express NF-kB, they may be more susceptible to the mitochondrial degradation induced
by the influx of Ca2+ by polybrene, although more experimentation needs to occur to confer that
hypothesis.
Our study revealed interesting implications for Vpr polymorphisms in the life cycle of
HIV-1 infection. We have shown that in resting primary cells, both R77Q and R36W result in
decreased apoptosis while the Vpr Null virus resulted in increased apoptosis. Additionally, we
have found that R77Q results in increased viral production as measured by p24. While it is
unclear how the above results correlate with the RP and LTNP phenotypes, they help to provide
a clearer picture of the role of Vpr during infection.
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CHAPTER III: CHARACTERIZATION OF TWELVE NOVEL BACILLUS PHAGES

Authors: Jacob Fairholm, Benjamin Ogilvie, Weston Hutchison, Jackson Tobler, Colton
Shaner, Alex Rhead, Emily Cluff, Rebecca James, Emily Lavering, Trever Thurgood, Richard
Robison, Julianne Grose
This chapter was taken from a publication in preparation for submission at the time of writing of
this thesis.
Abstract
Bacillus anthracis is the causative agent of anthrax, a lethal human and animal disease.
Bacteriophage, or phage, can be an effective way to identify the presence of bacterial
contamination, treat infection, and promote further understanding of the bacterial life cycle.
Thus, the continual isolation and characterization of novel phages capable of infecting B.
anthracis is important to better understand this pathogen. We isolated and characterized twelve
novel B. anthracis phages from soil samples taken throughout the western United States. Their
genomes were sequenced and subsequently annotated through DNA Master analysis and
BLASTp search. Each gene that could not be annotated by BLASTp was run through Phyre2 in
order to predict a function based off shape. In order to better understand their genetic
relationships to one another and to other previously published Bacillus phages, a dotplot analysis
was performed using the full genomes. Further phylogenetic analysis was performed using the
portal and tail fiber genes. These twelve phages clustered into four distinct clusters that were all
related to previously identified groups of phages. We believe that by characterizing these phages,
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they can be used in further efforts to better understand the evolutionary relationship of Bacillus
and Bacillus phages as well as serve as potential tools in the fight against anthrax infection.
Introduction
Bacillus anthracis is a gram-positive, anaerobic bacterium that is the known cause of the
disease anthrax in humans and animals. B. anthracis is a member of the B. cereus group, a group
of closely related bacteria including the soil microbe B. cereus and the insect pathogen B.
thuringiensis (80). Like all members of the genus Bacillus, B. anthracis forms spores that are
capable of surviving for extended periods of time with very little metabolic activity (83). Due to
this ability and the severity of anthrax infection, B. anthracis is considered a Tier 1 select agent
by the Centers for Disease Control and Prevention.
Bacteriophages, phages for short, are viruses that infect bacteria. Because of their ability
to infect and kill bacterial pathogens, phages have long been considered as an alternative to
traditional antibiotics. The first B. anthracis phage was isolated from wastewater in 1930 (85). It
was then shown to be protective of mice against anthrax infection, but only if the bacteria had
been infected by the phage prior to infecting the mouse (100). Since then, B. anthracis phage
have been used to diagnose anthrax infection, particularly Gamma phage because of its high
specificity to B. anthracis strains and not to other members of the B. cereus group (88).
Modifications to the Gamma phage detection assay have been used to identify B. anthracis
contamination of milk and ground beef as well as the early detection of germinating spores (91,
92). These advancements are important for the continual protection against bioterrorism attack
using B. anthracis.
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In addition to being useful for diagnostics or therapies, phages have long been known to
alter the characteristics of the bacteria they infect. Transduction is the process by which a phage
introduces new genetic material to the bacterium they have infected (134). Many bacteria, like
certain strains of Escherichia coli are only pathogenic because of virulence factors introduced by
transduction (135). Antibiotic resistance can also be conferred by phage-mediated horizontal
gene transfer (136). In B. anthracis, it has been shown that phage infection can allow the bacteria
to grow more effectively in earthworms and plant root nodules, perhaps explaining how the
vegetative bacterium is able to survive in soil (137). Thus, when new phages are isolated, it’s
important to fully characterize their genomes to identify potentially dangerous genes that could
lead to transduction and enhancement of bacterial virulence.
In this paper we announce the complete genomes of twelve novel B. anthracis phages
that were isolated from soil in the western United States. Full genome dotplot analysis showed
how these phages relate to one another and the analysis of the portal protein revealed how they
relate to previously described phages. Annotation of the phage genomes reveals numerous sigma
factors and sporulation genes that may impact the bacterial life cycle. Further analysis of the
phage proteins using Phyre2 identified 137 proteins that were annotated by BLASTp. Finally,
analysis of the tail fibers provides additional clues to the evolutionary origins of these phages as
well as possible host range implications. These findings provide additional resources for future
phage-based technologies.
Materials and Methods
Phage Isolation
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The phages in this study were isolated from soil samples collected in Utah, Idaho, and
Nevada according to the GPS coordinates provided in Table 1. At each location about 10 grams
of soil was collected a few inches below the grass or within the topsoil, and obvious debris and
foreign objects were removed. The soil samples were kept in sealed bags until seeded in
enrichment culture with LB broth inoculated with B. anthracis Sterne at 37°C. The resulting
culture was centrifuged to pellet the bacteria and debris and the supernatant was passed through a
0.45 μm filter. The filtrate was then used in a plaque assay by incubating with fresh bacteria
followed by plating with LB top agar. If plaques formed, a sterile loop was used to collect a wellisolated plaque, which was subsequently used to then re-infect the Sterne culture and perform a
secondary plaque assay. This process was performed at least three time to ensure that pure phage
isolates were collected.
DNA Sequencing and Annotation
Phage genomic DNA was isolated using the Phage DNA isolation kit from Norgen
Biotek (Canada). Genomic DNA was then prepared for sequencing by adding unique barcodes
using the Illumina TruSeq DNA Nano kit, then sequenced using the Illumina HiSeq 2500
platform with 250-bp paired-end reads at the Brigham Young University DNA Sequencing
Center (Provo, UT). Geneious version R11 was used for de novo contig assembly. All 12 phages
circularized upon assembly and base pair 1 was called by BLASTn alignment with the closest
related phage published. Annotations were performed using DNA Master and GeneMarkS gene
prediction software using their default settings. Gene functions were predicted through a
BLASTp search.
Phylogenetic Analysis
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Both full genomic nucleotide sequences and the amino acid sequences of the major portal
proteins were used for phylogenetic analysis. Dotplots were generated using Gepard and clusters
were identified by 50% or greater genomic synteny. Kalign was used to calculate the average
nucleotide identity (ANI) and to generate phylogenetic trees. BLASTp searches of the portal
protein were used to identify closely related phages.
Table 1: Twelve Novel Bacillus Phages. Cluster #, # of ORFs, genome size, and location of isolation
included
Phage
Name

Cluster #

Abinadi

1

Emiliahah
Erita

# of
ORFS

Genome Size (kb)

City/State

GPS Coordinates

294

158

Provo, UT

40.27872, -111.64418

1

251

158

Idaho Falls, ID

43.61243, -111.87406

1

137

101

Provo, UT

40.25063, -111.65598

McCartney

1

258

158

Idaho Falls, ID

43.61268, -111.90401

MrDarcy

2

267

165

Provo, UT

40.24784, -111.64833

Nate

2

286

167

Lamoille, NV

40.69160, -115.47420

SkyWalker

2

257

161

Lehi, UT

40.42849, -111.82623

Sophrita

2

266

168

Provo, UT

40.23906, -111.64995

Athena

3

65

37

Lehi, UT

40.42849, -111.82623

McDreamy

3

64

37

Provo, UT

40.26952, -111.63923

McSteamy

4

59

39

Provo, UT

40.26461, -111.64975

Booya

4

61

40

Provo, UT

40.24030, -111.64993

Phyre2 Analysis
Following genome annotation, all uncharacterized or hypothetical gene products were
analyzed using the protein modelling software Phyre2. A confidence value of ≥80% was used as
a threshold for significance. All results below this threshold were omitted from further analysis.
Results
Isolation and Annotation of Twelve Novel Bacillus Phages Reveals Four Clusters of Related
Phages
Twelve novel phages that infect B. anthracis Sterne were isolated from the western
United States, fully sequenced, and annotated using DNA Master and GeneMarkS (Table 1). The
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genomes ranged in size from the largest at 167 kb (Nate) to the smallest at 37 kb (McDreamy).
The largest observed number of open reading frames (ORFs) per phage was 294 (Abinadi) while
McSteamy had the least number of ORFs at 59.

A)

B)

Figure 3.1: Dotplot Analysis Reveals Four Distinct Clusters. The whole genome nucleotide sequences A) and portal protein amino
acid sequences B) of all 12 novel Bacillus phages were run through Gepard to generate a dotplot. Phages clustered into 4. Phage
names are listed on the y-axis in the order they appear on the dotplot. The order is repeated on the x-axis. Diagonal lines
represent areas of high similarity. Boxes outline each cluster with colors corresponding to each individual cluster. Blue is Cluster
1, Red is Cluster 2, Green is Cluster 3, and Yellow is Cluster 4.

In order to understand how these twelve phages were related to one another we analyzed
the full genomes of all twelve phages through Gepard in order to generate a dotplot. Gepard
functions by comparing two input sequences and creating a dot wherever the two sequences are
the same (138). Thus, it is an effective tool to determine the relationships between two genomes.
This analysis revealed four distinct clusters (Fig. 3.1A). The phages that comprised Cluster 1
include Abinadi, Emiliahah, Erita and McCartney, while Cluster 2 included MrDarcy, Nate,
SkyWalker, and Sophrita. Clusters 3 and 4 included only two phage each: Athena and
McDreamy in Cluster 3 and Booya and McSteamy in Cluster 4. The division of these phages into
these clusters was also consistent with similarities in the basic phage properties of genome size
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and number of ORFS between members of the same cluster (Table 1). To confirm the results of
this whole genome dotplot analysis, we generated new dotplots using the amino acid sequence of
the portal protein of each phage. The resulting dotplot revealed the same clustering as the
original whole genome analysis, providing further evidence that the clustering is correct (Fig.
3.1B).
After we determined how our twelve phages were related to one another, we sought to
determine how they were related to other published phages. To that extent, the amino acid
sequences of the portal protein of one representative from each cluster was subjected to a
BLASTp search. The portal protein was chosen for analysis instead of the major capsid protein,
which is typically used to determine phage relationships, because the annotation of the phages
comprising Cluster 2 did not reveal any putative major capsid protein. Dotplots comparing the
portal protein amino acid sequence of all related phages were then generated using Gepard (Fig.
3.2). Emiliahah served as the representative of Cluster 1. The BLASTp search of Emiliahah’s
portal protein revealed 54 related phages, most of which were other Bacillus phages (Fig. 3.2A).
However, two phages, Xoo-sp15 and f2b1, had Xanthomonas and Staphylococcus as their natural
hosts, respectively. The BLASTp search of MrDarcy, the Cluster 2 representative revealed only
14 phages. The first seven related phages were Bacillus phages while the remaining seven were
Lactococcus phages (Fig. 3.2B). Athena served as the Cluster 3 representative. The BLASTp
search was modified to reveal only Caudovirales as the initial search revealed only bacteria,
indicating the possible presence of prophages. There was also a wider variety of natural hosts for
the Cluster 3 related phages, with Clostridium, Caldibacillus, Lactobacillus, Paenibacillus, and
Butyrivibrio phages all represented among the 12 related phages. Interestingly, none of the
phages related to Athena were Bacillus phages. (Fig. 3.2C). The Cluster 4 representative was
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Booya, whose BLASTp search was also modified for only Caudovirales. There were 14 related
phages, nine were Bacillus phages, four were Clostridium phages, and one each were
Paenibacillus and Geobacillus phages (Fig. 3.2D).

B)

A)

C)

D)

Figure 3.2: Dotplot of Phages Related to Each Cluster. A) Dotplot of phages related to Cluster 1. There were 54 phages
that were related to Cluster 1’s representative Emiliahah. B) Dotplot of phages related to Cluster 2. MrDarcy served as
the Cluster 2 representative. There were 14 phages related to MrDarcy, 7 were Bacillus phages (black) and 7 were
Lactococcus phages (yellow). C) Dotplot of 12 phages related to Cluster 3. Athena served as the Cluster 3
representative. Font colors correspond to the host from which each phage was isolated, black for Bacillus, yellow for
Clostridium, blue for Caldibacillus, green for Lactococcus, red for Paenibacillus, and purple for Butryivibrio. D) Dotplot of
phages related to Cluster 4. Booya served as the Cluster 4 representative. Font color corresponds to natural host of each
phage, Black for Bacillus, blue for Clastridium, green for Geobacillus, and yellow for Paenibacillus.
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The members of Cluster 1 (Abinadi, Emiliahah, Erita, and McCartney) are related to the
Bastille-like group of phages, a well characterized group of Bacillus phages. Bastille-like phages
belong to the Spounavirinae subfamily of the Myoviridae family of viruses (139). These phages
tend to have genomes around 150 kb in size (140), which is true for all phages in Cluster 1, with
the exception of Erita whose genome is only 101 kb (Table 1). Further, it has been proposed that
the presence of type 1 thymidylate synthase and dihydrofolate reductase genes can be used as an
indicator of Bastille-like group phages (141). This requirement was met within the first 25 genes
of Emiliahah, Erita, and McCartney and within the last 25 genes of Abinadi. Taken together, this
evidence shows that Abinadi, Emiliahah, Erita, and McCartney should be added as members of
the Bastille-like group.
Cluster 2 phages (MrDarcy, Nate, Skywalker, and Sophrita) are related to a less welldefined group of Bacillus phages including vB_BanS_Tsamsa, Izhevsk, pW2, PBC2, and
vB_BcoS_136. These phages are large members of the Siphoviridae family with genomes
greater than 160 kb in size (142-145). These phages infect B. cereus group members and exhibit
limited host range within that group. The portal protein of Cluster 2 representative MrDarcy also
showed similarity to members of the Lactococcal 949 phage group which are also members of
the Siphoviridae family (146). This suggests that similar DNA packaging and delivery
mechanisms may exist between the 949 group and the Tsamsa-like group, although more
research is necessary.
Interestingly, Cluster 3 was unique in that the BLASTp search of Athena’s portal protein
did not reveal any closely related Bacillus phages. Instead, Cluster 3 appears most closely related
to a group of Clostridium phages known as the phiMMP04-like group which includes
phiMMP04, phiCD506, and JD032. phiMMP04-like phages are all temperate phages with
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genomes around 30 kb in size and were isolated by inducing prophage expression in the host
strain (147-149). The Caldibacillus phage CBP1 and the Lactobacillus phage iA2, which also
showed relatedness to Cluster 3, are also temperate phages (150, 151). As the initial BLASTp of
Athena’s portal protein revealed only bacterial relatives, indicating that Athena and McDreamy
may also be capable of establishing temperate infection, although further investigations are
needed to confirm this hypothesis. Only the Butyrivibrio phages Arawn, Bo-Finn, and Arian
were isolated during lytic infection (152). However, the authors of that study predicted that
Arawn was also capable of establishing temperate infections.
Finally, the BLASTp search of Cluster 4’s representative, Booya, revealed that Booya
and McSteamy are closely related to Gamma phage, and join the well-known Wbetavirus genus.
Gamma phage was first identified in 1955 as a lytic variant of the B. cereus phage W that was
identified a few years earlier (86, 87). Wbetaviruses have genomes between 35-40 kb with
between 50 and 55 ORFs (153, 154). While both Booya and McSteamy have genomes within
this size range, they have slightly more ORFs with 61 and 59 respectively. Booya was also
related to several Clostridium phages. phiSM101 is described as an episomal prophage, while
phi3626 was isolated by UV induction (155, 156). This could have implications on the ability of
Booya and McSteamy to integrate into the host genome.
Protein Structure Analysis Revealed Predicted Functions of 137 Hypothetical Gene Products
Following genome annotation using BLASTp, the genes that were still uncharacterized
were analyzed using the protein modeling software Phyre2, which functions by predicting a
protein’s structure and matching the structure to those of previously published proteins with
known functions. The function of the novel protein can then be predicted since protein structure
often predicts function. Over 1,000 uncharacterized genes were analyzed from all twelve phages.
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137 of those genes analyzed produced results with a confidence value above 80%, our
significance cut off. Many of these products are previously uncharacterized enzymes such as
hydrolases and transferases (Table 2). Some other notable characterizations are gene regulation
proteins and transcription factors, cell cycle regulation proteins, and DNA- and RNA-binding
proteins. The presence of genes that encode these proteins within the phage genomes could
indicate that infection with these phages modulates the B. anthracis lifecycle.
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Table 2: Novel Gene Products Identified by Phyre2. Number indicates gene product number.
Likely protein function

Abinadi

Emiliahah

Erita

McCartney

Endothelial cell adhesion

MrDarcy

Nate

SkyWalker

194

213

46

Sophrita

AimR transcriptional regulator

Athena

McDreamy

McSteamy

Booya

27

46

26

29

Cell cycle

21

Contractile protein

279

DNA-binding protein

58, 151

Galactose-binding domain

64, 94
51, 80, 108,
125

90
77, 104

123

198

251

44, 233

103
18, 172,
189

152, 240

41

32

213

HAD-like

290

Hydrolase

45

85, 93

Ligase

118

24

Membrane protein

116

232

89

61, 113

205

84
152

Nuclease

49, 114

Nucletotidyl transferase

123

Oxidoreductase

120

Protein transport

220

Recombination

45, 104

101

Ribosome

126

130
29

Signaling protein

29

24

26

122, 125

Structural genomics

132

23, 62, 138,
166

Structural protein

23

233

Transcription

149

202

131

Transport protein

8

45

40

18
74

230

198, 204

83

61

41
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Tail Fiber Analysis Reveals Similar Clustering as Dotplot Generation and has Interesting
Implications for Host Range
We next wanted to investigate whether the clustering of the phages correlated with
specific host ranges. Using Kalign, we created a phylogenetic tree using the amino acid sequence
of each tail fiber (Fig. 3.3). Cluster 1 phages each had two distinct tail fiber proteins, so both
were used in this analysis. The
tail fibers clustered similarly as
the dotplots in figure 3.1 with
several exceptions. First, the tail
fiber 1 of Abinadi did not cluster
with the other tail fiber 1’s of
Cluster 1. Instead, it is distantly
Figure 3.3: Phylogenetic Tree of Tail Fibers. The amino acid sequence of
each tail fiber was used to create a phylogenetic tree with Kalign. Cluster
1 phages had two distinct tail fibers, so both were used. Clustering was
similar to that seen with the dotplot analysis. Blue represents Cluster 1
tail fibers. Red represents Cluster 2 tail fibers. Green represents Cluster 3
tail fibers. Yellow represents Cluster 4 tail fibers.

related to the tail fibers of
Cluster 2. Additionally, the tail
fibers of Cluster 3, Athena and

McDreamy, did not group together.
Because tail fibers are used for attachment to the host, we wanted to see if BLASTp
searches of the tail fiber amino acid sequences could provide a hint at each phage’s host range.
Using the metadata provided by a BLASTp search of the tail fibers, we identified the host
organisms used to isolate the top five most closely related phages for each of our twelve novel
phages (Table 3). The closest tail fiber relatives of Clusters 1, 2, and 4 are all other Bacillus
phages, although in some cases it’s not clear which Bacillus species serve as the natural host.
Similar to the BLASTp searches of the portal proteins, Cluster 3’s closest tail fiber relatives were
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not Bacillus phages, but rather phages of other members of the Firmicutes phylum. This suggests
that Athena and McDreamy may be able to infect members of this phylum in addition to B.
anthracis from which they were originally isolated.
Table 3: Preferred Host of Closest Tail Fiber Relatives. The top 5 BLASTp hits were included.
Phage

Cluster #

Abinadi

1

Hosts of 5 closest relatives
B. thuringiensis kuristaki, B. thuringiensis DSM 350

Emiliahah

1

B. cereus, B. thuringiensis kuristaki, B. megaterium

Erita

1

B. cereus, B. thuringiensis kuristaki

McCartney

1

B. cereus, B. thuringiensis kuristaki

MrDarcy

2

B. cereus, B. anthracis

Nate

2

B. cereus, B. anthracis

SkyWalker

2

B. anthracis, B. cereus

Sophrita

2

B. cereus, B. anthracis

Athena

3

Exiguobacterium, Leuconostoc, Caldibacillus, Geobacillus

McDreamy

3

Exiguobacterium, Leuconostoc, Caldibacillus, Geobacillus, B. halmapalus, Enterococcus faecalis

McSteamy

4

B. anthracis, B. cereus

Booya

4

B. anthracis, B. thuringiensis israelensis

Discussion
Bacteriophages are believed to be the most abundant life form on Earth, with an
estimated 1031 individual phage particles in existence (84). As such, they represent a treasure
trove of novel biological molecules and are an essential component of the bacterial life cycle.
Thus, the continuous discovery and characterization of novel phages is not only important to
understanding complex microbial ecosystems, but also to better controlling diseases.
In this study, we described the isolation and characterization of twelve novel phages that
were capable of replicating in Bacillus anthracis Sterne. Whole genome analysis revealed that
these phages clustered into four distinct clusters. This clustering was confirmed by the analysis
of the phage’s portal proteins. These phages constitute additions to previously described Bacillus
phage groups: Cluster 1 phages are able to join the Bastille-like phage group, Cluster 2 phages
are able to join the Tsamsa-like group, and Cluster 4 phage are able to join the Wbetavirus
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genus. Interestingly, the Cluster 3 phages were not closely related to any previously identified
Bacillus phages, but rather were most closely related to temperate phages of Clostridium and
other common gut bacterial taxa such as Lactobacillus and Butyrivibio. B. cereus has long been
known as a cause of food poisoning and gastrointestinal anthrax is a rare, but known form of
infection, thus it is possible that phages that infect gut microbiota have evolved to infect
members of the Bacillus genus as well (157, 158).
In addition to expanding the number of known Bacillus phages, our study has identified
many potential gene products that warrant further study. The presence of genes that encode
transcriptional regulators, cell cycle regulators, and RNA- and DNA-binding proteins suggest
that infection by our phages could result in drastic changes to the bacterial life cycle. For
example, while it is currently unclear how vegetative B. anthracis survives in soil, it has been
hypothesized that phage infection could play an important role (137). Additionally, phage
derived enzymes, such as hydrolases, holins, and lysins can be used in a number of molecular
biology techniques including as antimicrobials (101, 159). In fact, a lysin produced by Gamma
phage, PlyG, has been shown to be a highly effective antimicrobial tool against anthrax
contamination (102, 103). Because Cluster 4 is so closely related to Gamma phage, it’s possible
that they too can produce molecularly useful proteins.
Phage therapy, or the treatment of bacterial infections by using phage capable of lysing
the bacteria in question, has been a growing area of research, especially amid the increasing
incidences of antibiotic resistance. A number of phage therapies have been used to successfully
treat infections by various common bacterial pathogens including Escherichia coli,
Pseudomonas aeruginosa, and Staphylococcus aureus (99). One obstacle to the widespread use
of phage therapy is that phages often introduce new antibiotic resistance genes as well as other
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harmful genes to the bacterial host, creating an even bigger problem for the infected individual
and public health as a whole (160). Thus, it is important to thoroughly annotate the genomes of
all phages, looking for any potentially harmful genes, before using them in a phage therapy.
Although no phage therapy exists to treat anthrax infection, the continual discovery and
characterization of B. anthracis phages will provide future scientists and physicians with a
variety of phages if the need ever arises.
Phages continue to be a source of increased knowledge and resources in the world of
microbiology and molecular biology. The twelve novel B. anthracis phages presented in this
study provide existing new opportunities to learn more about how phages impact the bacterial
life cycle as well as new sources of molecular tools and therapies. Further research is needed to
fully unlock their potential.
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CHAPTER IV: CONCLUSION
Discussion
Since its origin in 1892, the study of viruses has shaped our understanding of disease and
the fundamentals of life. While human viruses continue to be a scourge on humanity, bacterial
viruses have been turned into tools to combat infection and to better understand molecular
biology. In this thesis, we have sought to better understand how different polymorphisms in a
small, accessory protein of HIV-1 result in differences in disease progression. We have also
isolated and characterized 12 novel bacteriophages against Bacillus anthracis that hold potential
as therapeutic and molecular tools. While there is still much to be learned about these distinct
viruses, the work in this thesis can serve as a steppingstone to further discovery.
The role and function of viral protein R of HIV-1 has been the subject of intensive
research for over thirty years. This research has highlighted two Vpr polymorphisms that result
in differences in how quickly a patient develops AIDS. While it is believed that the R36W
polymorphism results in rapid progression and the R77Q polymorphism results in long-term nonprogression, the mechanism behind these differences in phenotype are still unclear. Previous
work in this lab has shown that in cancerous cell lines R36W results in increased viral load as
measured by RNA content and virion production as well as increased cell death by necrosis in
cancerous cell lines. Meanwhile, R77Q results in increased cell cycle arrest in the G2 phase and
increased cell death by apoptosis. In this thesis, we sought to further this work by using
experimental models that better replicate human infection. Using primary CD4+ cells, we saw
that infection with R36W and R77Q harboring viruses may actually result in less apoptosis and
cell death, while infection with a Vpr knockout virus can result in increased apoptosis. Further
work needs to be done in order to have better confidence in the legitimacy of this data.
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B. anthracis continues to pose a threat to the health of both humans and livestock. It’s
ability to form durable spores that are easily disseminated as well as the severity of anthrax
infection have caused the CDC to list B. anthracis as a Tier 1 select agent. The discovery of
novel phages capable of infecting B. anthracis serves as an opportunity to better understand the
bacterial life cycle and as a potential treatment to infection. Herein we have described 12 novel
B. anthracis phages. These 12 phages group into four distinct clusters that are related to other
previously described Bacillus phage groups. Interestingly, the Cluster 3 phages were related to a
group of Clostridium phages that were known to establish temperate infection. Further, we
showed that their tail-fibers could be indicative of their potential host ranges. Finally, we have
annotated hundreds of new protein products that could be used to better understand how
infection by a phage affects the bacteria’s ability to survive in soil.
Future Directions
As is the case of most research, while attempting to answer the questions presented in this
work, new questions have arisen. Further study of the infection of primary cells with our four
virus strains is needed to better understand the effects of the Vpr polymorphism. It is possible
that the decrease in apoptosis seen by R77Q in infected primary cells was a result of increased
G2 arrest leading to enhanced reverse transcription. To confirm this hypothesis, assays need to
be done to determine how infection with each variant affects the cell cycle in primary cells.
Further, a Q-RT-PCR study could be undertaken to monitor for products of reverse transcription
in order to see if reverse transcription is being partially or fully completed. While knowing that a
polymorphism does or does not induce apoptosis is interesting, understanding the mechanism
behind the phenotype is even more valuable. Thus, a study of which caspases are or are not
activated will shine greater light on the differences occurring with infection by each virus
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variant. Another interesting line of investigation into the effects of infection with each Vpr
variant would be an RNA-seq assay. This would show differences in host cell protein expression
as a direct result of infection with each different Vpr polymorphism, allowing for a better
understanding of how R36W and R77Q cause either rapid progression or long-term nonprogression.
Unfortunately, we were unable to perform any infections of humanized mice. An in vivo
study of Vpr polymorphisms in humanized mice would provide a lot of insight into how these
polymorphisms actually result in differences in disease progression. Utilizing peripheral blood,
differences in viral load can be measured by the quantification of viral nucleic acids using Q-RTPCR. Differences in the induction of apoptosis and cell death can again be measured by staining
peripheral white blood cells with Annexin V and FVD. As AIDS is defined in humans as a drop
in CD4+ T cells below 200 cells per μl of blood, using humanized mice we can monitor for
CD4+ T cell levels in both peripheral blood and lymphoid organs. In this way, we can determine
which polymorphism results in a faster decrease in CD4+ T cell levels, potentially explaining the
differences in disease phenotype. The immune response to infection with each virus can also be
monitored. Thus, a humanized mouse study can provide a lot of deeper understanding of Vpr’s
role in disease progression.
Additional characterization of our twelve novel phages needs to be performed before they
can be used in a potential phage therapy. First, the host range of each phage needs to be
determined. In order to be useful as an anti-B. anthracis therapy, the host range of the phages
needs to be limited to strains of B. anthracis and no other members of the B. cereus group.
Further, the functions of the still unknown genes need to be determined. This is to ensure that the
phages aren’t carrying any antibiotic resistance genes that could be horizontally transferred to the

68

bacteria when the phages are used as therapeutics. Additionally, only lytic phages are useful as a
therapy. Since the phages of Cluster 3 could potentially establish temperate infection, their life
cycle within their Bacillus host needs to be investigated. We have proposed that some of the
genes annotated within these twelve phages could play a role in the ability of B. anthracis to
survive in soil. Thus, a study into this possibility would shed greater light on the phage/host
dynamic.
Virology is an ever-growing field. As we continue to study viruses, we will better
understand how they cause disease and thus learn to better control and treat infection. Many
papers have sought to explain the role of Vpr polymorphisms in disease progression. Herein, we
have attempted to provide a more accurate model by infecting primary cells with whole,
replication competent HIV-1. Further, we have identified and characterized 12 novel phages with
potential therapeutic uses. While the work of this thesis was informative, there are many
questions that are left unanswered.
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